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ABSTRACT

GLUTAMINE TRANSPORTERS IN HUMAN HEPATOCELLULAR CARCINOMA AND IN
THE EMT6 MAMMARY TUMOR AND ADJACENT STROMA OF THE SYNGENEIC
BALB/C MOUSE MODEL

Clare Kron, Ph.D.
Department of Biological Sciences
Northern Illinois University, 2017
Barrie P. Bode, Director

Human hepatocellular carcinoma (HCC) is an increasing threat worldwide due to cirrhosis of the
liver developing from viral hepatitis and non-alcoholic steatohepatitis (NASH). Breast cancer is
the second leading cause of cancer death in American women, with the most intractable type
classified as triple negative. Both cancers depend on glutamine as the major oxidizable substrate
for tumor growth, therefore, identification of glutamine transporters and transporter activity is of
vital importance in the development of treatment options. It is well documented that ASCT2 is
the major glutamine transporter in both cancers but little is known regarding the relative amounts
of additional glutamine transporters that operate in these primary and metastatic tumors. Studies
using thirteen HCC cell lines investigated eight glutamine transporters via gene expression
studies, Western blot assays, and functional analysis. None of the studies, however, incorporated
the tumor microenvironment (the stroma), the vital interacting feature of actual tumor growth. In
vivo studies were then completed using the EMT6 cell line, a murine mammary carcinoma from
a BALB/c laboratory mouse with characteristics of triple negative human breast cancer (TNBC).
To distinguish cancer cells from stromal cells, EMT6 was transfected with antibiotic-selective
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green fluorescent protein (GFP) prior to injection into the mammary fat pads of the genetically
identical BALB/c mouse. In vitro results showed that HCC and EMT6 cell lines were glutamine
dependent, obtained the majority of glutamine via ASCT2, and used several transporters that
were differentially expressed, though transporter activities, cognate mRNA, and protein
expression levels were discordant. In vivo mammary carcinoma results showed an increase in all
expression levels of transporters, receptors, and enzymes compared to the in vitro EMT6 cell
line. EMT6-GFP transfected tumor cells nearly universally induced greater mRNA expression
compared to unmodified tumor cells used as a control. The results of this project highlighted the
complex and layered regulation between gene expression and physiological activity in vitro, and
the changes of mRNA expression in vivo due to both stromal involvement and the effects of
antibiotic-selective transfection.
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GENERAL INTRODUCTION

Importance of Studying Amino Acid Transporters

Glutamine transporters have an ever-expanding history in cancer research as they have
been implicated in a wide variety of human cancers including human hepatocellular carcinoma
(hHCC) and breast cancers. Among the amino acids responsible for the proliferation of tumor
cells, glutamine is recognized as a key component of cancerous transformation which is
characterized by changes in transport and metabolism of key nutrients. As the most abundant
free amino acid in the body, with a concentration of about 500–900 µmol/l (Brosnan, 2003),
glutamine has pleiotropic roles in cellular metabolism including its role as the major intercellular
nontoxic ammonia shuttle, which is utilized in the urea cycle, transamination reactions, and
gluconeogenesis. It serves as a metabolic intermediate that contributes carbon and nitrogen for
synthesis of other amino acids, nucleic acids, fatty acids, and proteins. As the major source of
cellular glutamate, glutamine can be the rate-limiting step in the synthesis of glutathione, an
antioxidant that protects cells from oxidative stress. It also coordinates protein translation,
metabolic flux, and nitrogen balance to maintain tissue homeostasis (Souba, 1993), making it
conditionally essential during the expansion of cancer cells. Due to its many functions, glutamine
is being explored as a potential therapeutic and diagnostic target in oncology (DeBerardinis &
Cheng, 2010); (Hensley, Wasti, & DeBerardinis, 2013). Broad statements regarding key
transporter activity, however, must be modulated in accordance with individual studies of
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specific cancers. Variables in transporter type and abundance, affinity for a given amino acid,
transporter availability based on intracellular as well as extracellular amino acids, and
transmembrane electrochemical potentials all influence the metabolic activity of the proliferating
cancer cells.

CHAPTER 1
INTRODUCTION

Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is a primary malignancy of the liver which occurs
predominantly in patients with underlying chronic liver disease and cirrhosis (Allison, 2005), a
diffuse hepatic process characterized by fibrosis and conversion of the normal liver architecture
into structurally abnormal nodules which occurs over weeks to years (D. C. Wolf, 2017). HCC is
now the third leading cause of cancer deaths worldwide, with over 500,000 people affected
(Cicalese, 2016). The highest incidence of HCC occurs on the Asian and African continents due
to the endemic high prevalence of two transmissible inflammatory liver conditions, hepatitis B
and hepatitis C, which strongly predispose to the development of HCC.
The threat of HCC is expected to continue to grow in future years (Llovet, 2004).The
peak incidence of HCC associated with hepatitis C virus (HCV) infection has not yet occurred,
and as the condition of cirrhosis continues to increase due to nonalcoholic steatohepatitis
(NASH), the inflammatory type of nonalcoholic fatty liver disease (NAFLD), HCC will also
increase. The obesity epidemic in the U.S. fuels the onset of cirrhosis as NASH typically
develops in the setting of obesity, type 2 diabetes, dyslipidemia, and hypertension (Bugianesi,
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2007). Developing effective care for patients with HCC is a critical need as there are no current
effective therapies and the prognosis is poor (Villanueva, Hernandez-Gea, & Llovet, 2013).
Methods such as quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR)
for detecting gene expression, and Western blotting for protein expression have revealed two
coordinately upregulated amino acid transporters, ASCT2 and LAT1. These two transporters
physically associate in the plasma membrane of cancer cells (Xu & Hemler, 2005) as well as
drive glutamine-dependent mTOR signaling (Fuchs & Bode, 2005). In cancerous human liver
cells, the transport of glutamine is almost exclusively mediated by ASCT2 (Bode et al., 2002).
LAT1 has also been highlighted as a diagnostic and prognostic marker in many human cancers
due to its ability to transport a broad variety of essential amino acids, drugs, pro-drugs and
imaging agents (Geier et al., 2013).

Importance of Glutamine

Glutamine, the most abundant non-essential amino acid in plasma, has been reclassified
as “conditionally essential” during critical illness as it is the major oxidizable substrate for tumor
cells (Lacey & Wilmore, 1990). Glutamine has many important cellular functions (Figure 1). As
the major intercellular nontoxic ammonia shuttle, it is utilized in the urea cycle, transamination
reactions, and gluconeogenesis. It serves as a metabolic intermediate that contributes carbon and
nitrogen for synthesis of other amino acids, nucleic acids, fatty acids, and proteins. As the major
source of cellular glutamate, glutamine can be the rate-limiting step in the synthesis of
glutathione, an antioxidant that protects cells from oxidative stress. One hypothesis states that
the primary role of glutamine in cancer is to release ammonia via deamidation for the acidic
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environment of the cancer cell (Huang et al., 2013). Glutamine also coordinates protein
translation, metabolic flux, and nitrogen balance to maintain tissue homeostasis (Souba, 1993).
Two enzymes function to maintain glutamine homeostasis: glutamine synthetase and
glutaminase (B. C. Fuchs & Bode, 2006). Glutaminolysis is necessary to replenish intermediates
for the TCA cycle, and to generate reductive power via NADPH (DeBerardinis et al., 2007).
Depressed glutamine synthetase rates concomitant with increased glutamine oxidation and
glutaminase rates have been reported in human HCC (Bode et al., 2002).
Tumor cell proliferation requires rapid synthesis of macromolecules including lipids,
proteins, and nucleotides (DeBerardinis et al., 2007). Glycolysis in the presence of abundant
oxygen (the Warburg effect) is typical of this state, and though the tricarboxylic acid cycle
(TCA) may be active, it is characterized by an efflux of substrates for use in biosynthetic
pathways such as fatty acid synthesis. This relies on the activation of pathways to generate
reductive power (NADPH) and to restore oxaloacetate for continued TCA cycle function. Both
needs are met by a high rate of glutamine metabolism concentrated in the hepatocytes of the
hepatic lobule in the liver. Transformed cells can engage in glutamine metabolism that exceeds
the requirement for protein and nucleotide synthesis. They can also exhibit a high rate of
glutamine consumption that cannot be explained by nitrogen demand. Rather, glutamine
metabolism provides a carbon source for biosynthetic precursors, and it has been noted that only
a few percent of glutamine is used by proliferating cells for biosynthesis (Yuneva, Zamboni,
Oefner, Sachidanandam, & Lazebnik, 2007).
Normally, the transport of glutamine across the plasma membrane of hepatocytes is
mediated largely by the two System N transporters SNAT3 and SNAT5 (Baird et al., 2004) in
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conjunction with the intercellular glutamine cycle (Figure 1). However, in cancerous human liver
cells, the greater proportion of glutamine transport is mediated by the System ASC transporter
ASCT2 (Bode et al., 2002). The emergence and dominance of ASCT2 in human HCC suggests
that it plays an essential role in HCC growth and survival; indeed, targeted silencing of ASCT2
in SK-Hep hepatoma cells leads to apoptotic cell death (B. C. Fuchs, Perez, Suetterlin,
Chaudhry, & Bode, 2004). Thus, ASCT2 has gained interest as a potential therapeutic target for
human HCC.
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Figure 1. Glutamine-Glutamate Cycles. Glutamine is broken down by glutaminase or glutamine
amidotransferases to glutamate. Glutamate is subsequently metabolized by glutamate
dehydrogenase or transaminases to 2-oxoglutarate (alpha-ketoglutarate) in the mitochondria,
where it enters the TCA cycle, and can either contribute to oxidative metabolism,
NADH/FADH2 production and ATP generation (via oxidative phosphorylation), or via reductive
carboxylation through isocitrate dehydrogenase (IDH1/2) contribute to the regeneration of citrate
for AcetylCoA production and fatty acid (membrane) biosynthesis via ATP Citrate Lyase.
Likewise, glutamine is regenerated by glutamine synthetase via the ATP-dependent condensation
of glutamate with ammonia. Alternatively, glutamate can be exported from the cell through
specific transporters and travel to adjacent cells where it is taken up and re-converted to
glutamine by glutamine synthetase via the ATP-dependent condensation of ammonia. Glutamine
synthesized by the glutamine synthetase pathway is often exported from the cell via specific
transporters as part of tissue glutamine cycles (Bode, 2017). (Adapted with permission.)
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`
Figure 2. The hepatic glutamine cycle features the two divisions of the hepatocyte, the major
parenchymal tissue of the liver (Haussinger, 1986) The periportal region, center of glutamine
consumption, involves the SLC38A5 transporter (SNAT5), and the perivenous region, center of
glutamine production involves the SLC38A3 transporter (SNAT3). The intercellular glutamine
cycle involves the enzyme, glutaminase (GLS), an amidohydrolase enzyme, to catalyze the
condensation of glutamate and ammonia, and the enzyme glutamate-ammonia ligase (GLUL) for
synthesizing glutamine from glutamate and ammonia.

The Family of Transporters

Previous studies by the author (unpublished) used qRT-PCR for a comprehensive gene
expression analysis of eight glutamine transporters in a panel of six epithelial (Group I) and
seven mesenchymal (Group II) human HCC cell lines. As solute carrier transporters may interact
with anticancer agents, knowledge of the function of these transporters may lead to methods of
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chemotherapeutic drug delivery (Nakanishi & Tamai, 2011). Various transport systems are
employed to transport amino acids across the plasma membrane, and two systems, System ASC
and System L, have been shown to be coordinately upregulated in many cancers, including
human HCC (Bode & Fuchs, 2005). The transporters responsible for these activities, ASCT2 and
LAT1, associate in the plasma membrane (Xu & Hemler, 2005). The investigation of ASCT2
and LAT1 per the research grant #2R15CA108519-02 (Bode, 2007), posed the broad question:
Do ASCT2 and LAT1 subserve the same function and regulation in all classes of human HCC?
Solute carrier families are based on amino acid sequence homologies (Hediger et al.,
2004). Of the many families of transporters, 55 Solute Carrier Families (SLC) mediate the uptake
of organic and inorganic substrates using several transport mechanisms (Figure 3). Twelve of the
SCL families have proteins that mediate amino acids across the cellular membrane, with four
defining levels: family, system, gene, and protein. The family name is the acronym SLC plus a
number (e.g., SLC1); the system defines the functional properties of the family (e.g., ASC:
alanine, serine, and cysteine-preferring); the gene name uses the family designation, its number,
the letter, “A,” (for amino acid transporter), and the member number (e.g., SLC1A5); and the
protein name varies based on both the original designation from past research and those currently
accepted by the research community.
The three SLC family members studied—SLC1, SLC7, and SLC38—are the most prolific
of the amino acid transporters, and they are expressed in most cells and tissues, where they
mediate the bulk of amino acid transport. SLC1 uses System ASC, indicating a preference for
small, neutral amino acids. A symporter mechanism is employed, using the Na+ electrochemical
gradient to drive the uptake of amino acids, notably glutamine (Kanai & Hediger, 2003). Of the
two members of the SLC1 family that manifest System ASC activity, ASCT2 is the main
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transporter of glutamine during cell transformation (Fuchs & Bode, 2005). Major results have
shown a 10-fold increase in glutamine uptake in HCC via ASCT2 (Bode et al., 2002).
Significantly, this transporter is not expressed in normal hepatocytes.
SLC7 uses System L, a sodium-independent antiport activity of neutral amino acids with
large, branched or aromatic side chains, such as leucine, phenylalanine and tryptophan, and it
employs an exchange mechanism in which an amino acid, notably glutamine, is exchanged for
another amino acid essential for cellular growth, especially leucine, which is known to be
essential in activating the growth-promoting kinase, mTOR. System L activity is mediated by
proteins within the SLC7 cationic/heterodimeric amino acid transporter family (Verrey et al.,
2004). Among these, LAT1 has been shown to be consistently associated with cancer. As LAT1
is both instrumental in the uptake of amino acids as well as the uptake of anti-cancer agent,
melphalan, it may be beneficial to either inhibit its expression or exploit its usage for therapeutic
activity. Working in concert with ASCT2, LAT1 acts as an antiporter, permitting the influx of
amino acids required for metabolic demands while effluxing the amino acids taken up by
ASCT2. This exchange mechanism could regulate the cytoplasmic amino acid pool (Fuchs &
Bode, 2005). Both transporters have been shown to physically associate in the plasma membrane
in other cancers (Xu & Hemler, 2005), and may, therefore, indicate a joint role in HCC growth
and survival. Studies have shown that depriving hepatoma cells of the LAT1 substrate, leucine,
induced ASCT2-mediated glutamine uptake, while glutamine deprivation induced leucine
uptake, thereby establishing a possible regulatory link between the two transporters (Wasa,
Bode, & Souba, 1996). Studies also showed that the counter transport of glutamine via ASCT2
and leucine via LAT1 controls mTORC1 (Nicklin et al., 2009).
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In contrast to Systems ASC and L, System N, one of the two subfamilies of the SLC38
sodium-coupled neutral amino acid transporters, is the normal major route of glutamine transport
for human hepatocytes (Kilberg, Handlogten, & Christensen, 1980); (Bode, Kaminski, Souba, &
Li, 1995). This group includes SNAT3 and SNAT5, which work in the perivenous and periportal
regions of the liver, respectively, to maintain systemic glutamine levels (Baird et al., 2004). As
cells transform, they switch to System ASC, which accounts for the 10- to 20-fold increase in
glutamine uptake (Bode et al., 2002). ASCT2, therefore, is a marker of malignancy in the liver.
The second subfamily of SLC38 is System A, which includes SNAT1, SNAT2, and SNAT4,
characterized by their transport of the synthetic amino acid substrate, N-(- methylamino)
isobutyric acid (MeAIB) (Mackenzie et al., 2003). It is of clinical interest to determine the usage
of Systems N and A upon the increased use of ASCT2 during malignancy (Fuchs & Bode, 2005).
A possible cellular benefit of switching to system ASC is its higher affinity for glutamine versus
that of system N or A. Two of the System A transporters, SNAT1 and SNAT2, have Km values
of 498 mM, and 1.65 mM, respectively (Yao et al., 2000). In a study of placental system A
activity, 14C-MeAIB uptake showed a Km of 45.4 ± 25.0 mM, which potentially represents
SNAT4 (Desforges, Greenwood, Glazier, Westwood, & Sibley, 2010). ASCT2, in contrast, has a
Km of 50-100 µM, allowing it to take up glutamine more efficiently at low ambient
concentrations (Kanai & Hediger, 2003).
A member of the SLC6 family of transporters, ATB0,+ (SLC6A14), has been shown to be
upregulated in tumors of epithelial origin, including colon cancer, cervical cancer, breast cancer,
and pancreatic cancer. Several amino acid-based prodrugs are recognized as substrates by
SLC6A14, and given the low expression of this transporter in normal cells, a possible treatment
strategy could deliver anticancer drugs into tumor cells without a major effect on normal cells.
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Figure 3. Amino acid transport mechanisms. Primary active transporters directly hydrolyze ATP
to pump substrates against their concentration gradients. Many ion pumps such as the Na+/K+ATPase use this mechanism to establish ion electrochemical gradients, which are in turn
harnessed as potential energy sources by secondary active symporters such as Na+-dependent
amino acid transporters to drive the uptake of their substrates against their concentration
gradient. Many amino acid transporters utilize an exchange mechanism to drive substrate
movement; when such antiport is dependent upon the maintenance of high levels of intracellular
amino acids via a secondary active transporter, the coupled arrangement is termed “tertiary
active transport.” The fourth category of transporter is facilitative, where the bidirectional
movement of a substrate is mediated by a protein and driven solely by its transmembrane
concentration gradient. Amino acid transporters are driven by facilitative, secondary active or
tertiary active mechanisms. In some cases, combinations of these mechanisms function at the
same time (e.g., a Na+-dependent amino acid exchanger) (Bode, 2017). (Adapted with
permission.)

ASCT2 and LAT1 in Cell Growth and Survival

Previous testing to verify glutamine requirements via ASCT2 for hepatoma survival
demonstrated that this transporter is essential beyond its role in glutamine uptake (B. C. Fuchs et
al., 2004). An inducible ASCT2 antisense RNA expression system was shown to reduce ASCT2
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mRNA levels and activity by up to 75%, with subsequent 98% cell death by apoptosis after 48
hours. However, glutamine starvation produced a more delayed effect, with 94% cellular loss
after 72 hours; thus, ASCT2 appears to participate directly in cell survival signaling. It is also
hypothesized that diminishing delivery of the precursors glutamine and cysteine leads to the loss
of the antioxidant glutathione, which results in apoptosis due to oxidative stress from transporter
knockdown (B. C. Fuchs et al., 2004). An alternative cause of apoptosis may be the loss of
glutamine as a catalyst of redox reactions in the TCA cycle, and not because it provides
biosynthetic precursors. Only a few percent of glutamine are used by proliferating cells for
biosynthesis (Yuneva et al., 2007)).
As Bode and Fuchs noted, enhanced expression of ASCT2 and LAT1 has been identified
in all human cell lines they had studied (Fuchs & Bode, 2005), and their coordinate enhanced
expression in several human cancers provides relevance to human physiology in vivo.

HCC Cell Line Types

Lee and Thorgeirsson (2002) characterized 19 human HCC cell lines using microarray
analysis, a method of measuring the relative abundance of nucleic acid sequences via probetarget hybridization. Two distinct groups of HCC cell lines emerged, strongly correlated with
degrees of α-fetoprotein (AFP) expression, the major liver-produced component of mammalian
fetal serum. Its expression is a 5- to 30-fold higher in subgroup I than in subgroup II. While its
normal expression is found in the endoderm of the yolk sac and in fetal liver, AFP is reactivated
in liver tumors, with high levels in 50-70% of HCC patients, hence, its current use as a serum
biomarker for HCC. This led to the theory that HCC originates from progenitor cells, oval cells,
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or their close descendants. Both groups showed tumorigenic features; however, a notable
distinction between Group I and II was the latter group’s up- and down-regulation of genes
involved in cell adhesion and extracellular matrix formation. The integrin α3β1 complex, known
to be associated with metastasis, was also upregulated in Group II. While both subgroups shared
many co-expressed genes, the overall pattern indicated a more metastatic profile for Group II
compared to Group I.
Another defining characteristic in determining the subgroups was the expression of either
E-cadherin, a cell-to-cell adhesion glycoprotein, or vimentin, an intermediate filament protein
(Lee & Thorgeirsson, 2002). Four of the cell lines previously studied (HepG2, Hep3B, Huh-7,
and PLC/PRF/5) expressed E-cadherin, leading to the classification of “epithelial” (Group I),
a.k.a. “oncofetal,” with more liver-specific (differentiated) characteristics. Seven of the cell lines
(SNU-182, SNU-387, SNU-475, Focus, SK-Hep, SNU-449, and SNU-398) were classified as
“mesenchymal” (Group II) because they expressed vimentin, with E-cadherin extremely
downregulated. Therefore, Group II over expresses vimentin, which has been observed to
coincide with metastasis in HCC, as a de-differentiated phenotype (B. C. Fuchs et al., 2008).
While competitive inhibition of ASCT2 transport was shown to inhibit the growth of several
Group II cells lines, it failed to arrest the growth of Group I, which is well-differentiated (Bode
et al., 2002). These studies suggested that some Group I HCC lines (specifically, Huh 7, Hep G2,
and Hep 3B) have a greater capacity to synthesize glutamine endogenously via glutamine
synthetase, thus are less dependent on transport. These cell lines also may retain some of the
features of normal hepatocytes, augmenting their glutamine supply via system N, the major
transporter for normal and fetal human liver.
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For laboratory experimentation, these results suggested that cell lines retain and express
the gene-expressions of in vivo phenotypes, allowing reasonable conclusions from in vitro
studies. The thirteen cell lines chosen for this study are divided into Group I and Group II, based
on the work of Lee and Thorgeirsson (2002).
Unpublished microarray tests by Hoshida Yujin indicated that all tested HCC cell lines,
including 10 of the lines studied for this report, expressed both ASCT2 and LAT1 in varying
ratios. Unpublished studies by the author had verified the microarray results with Quantitative
Reverse Transcriptase-Real Time-Polymerase Chain Reaction (qRT-PCR).

CHAPTER 2
MATERIALS AND METHODS

Cell Lines

The HCC cell lines used in this study were divided into two groups: epithelial (Group I)
and mesenchymal (Group II), based on microarray gene expression profiling (Lee &
Thorgeirsson, 2002) – modeling primary and metastatic carcinoma, respectively, and confirmed
by subsequent studies (B. C. Fuchs et al., 2008). The Group I cell lines examined were HepG2
(Knowles, Howe, & Aden, 1980), Hep3B (Knowles et al., 1980), Huh1 (Huh & Utakoji, 1981),
Huh7 (Nakabayashi, Taketa, Miyano, Yamane, & Sato, 1982), PLC/PRF/5 (Alexander, Bey,
Geddes, & Lecatsas, 1976) and Tong (Stevenson, Lin, Tong, & Marshall, 1987). The Group II
cell lines examined were SK-Hep1 (Fogh, Fogh, & Orfeo, 1977), Focus (He et al., 1984),
Mahlavu (Grimm, 1976), and a series of HCC lines from Seoul National University (SNU),
including SNU-449, SNU-475, SNU-387 and SNU-423 (Park et al., 1995). All cell lines were
obtained from American Type Culture Collection, except for Focus (from the Molecular
Hepatology Laboratories, MGH Cancer Center), Mahlavu, Tong, and Huh1 (from Dr. Bryan
Fuchs, Mass General Hospital) and Huh7 (from Dr. Jake Liang, Mass General Hospital). All cell
lines were subjected to short tandem repeat (STR) analysis by the Johns Hopkins University
Core Fragment Analysis Facility to confirm cell line identity; all were confirmed, with the
notable exception of a cell line originally identified as Huh2 (Huh & Utakoji, 1981) that was, in
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fact, the pancreatic cancer cell line MIA Paca-2 (Yunis, Arimura, & Russin, 1977). As it was not
an HCC cell line, it has not been retained in this study. All cell lines were maintained in growth
media, which is DMEM (high glucose) + 2 mM L-glutamine + 1% antibiotic/antimycotic
solution (all from Life Technologies, Grand Island, NY) + 10% fetal bovine serum (Hyclone,
Logan, UT) in a humidified atmosphere of 5% CO2 at 37°C.

Cell Culture

All cell culture media and additives were from Life Technologies (Grand Island, NY)
except for fetal bovine serum (Hyclone, Logan, UT). Chemicals were from Fisher Scientific
(Pittsburgh, PA) or Sigma (St. Louis, MO). Amino acid substrates, 2-aminobicyclo-(2,2,1)heptane-2-carboxylic acid (BCH), N-(α-methylamino)-isobutyric acid (MeAIB), L-Glutamic
acid γ-monohydroxamate (GGH), and L-Aspartic acid γ-monohydroxamate (ABH) were from
Sigma, and γ-L-Glutamyl-p-nitroanilide Hydrochloride (GPNA) was from MP Biomedicals
(Solon, OH). Radiolabeled (3H) glutamine and leucine were from Perkin-Elmer (Waltham, MA)
and MeAIB was obtained from American Radiolabeled Chemicals, Inc. (St. Louis, MO). All
consumables (tissue culture vessels, pipets, etc.) were from Fisher Scientific. The bicinchoninic
acid (BCA) protein detection reagent were obtained from Thermo-Pierce (Rockford, IL). Fulllength human ASCT2 cDNA was provided by Dr. Vadivel Ganapathy at the Medical College of
Georgia, and was subcloned into the pcDNA 3.1Hygro expression vector (Invitrogen, Carlsbad,
CA). Full-length human LAT1 cDNA in the pCMV6-XL4 expression vector was obtained from
Origene (Rockville, MD).
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Cell Line Management

Cell lines were grown in monolayer format, using 4.5 mg/ml, High Glucose Dulbecco’s
Modified Eagle Medium (DMEM) (Gibco; Grand Island, NY). Additives included 2 mM Lglutamine (Gibco, Grand Island, NY), 1% antibiotic/antimycotic solution (ThermoScientific;
Logan, UT), and 10% triple 0.1 µM filtered fetal bovine serum (Atlanta Biologicals;
Lawrenceville, GA) to support the specific needs of HCC cells. Cells were grown in 25 cm2
Falcon T-flasks with 0.2 µm Vented Blue Plug Seal caps (Becton, Dickinson and Co.; Franklin
Lakes, NJ) in a humidified incubator at 37o C with 5% CO2. Cells were allowed to reach
confluency (100% growth surface coverage), and were then transferred via trypsin displacement
(TrypLEzyme, Gibco; Grand Island, NY) to 150 mm x 25 mm plates (Corning; Corning, NY) to
increase in number. To standardize conditions of growth and nutrient status, all cell lines were
given new medium at 95%-100% confluency, and then harvested within 24 hours.

Extraction, Purification, and Concentration of RNA

Extraction and purification of RNA were completed using the Promega PureYield RNA
Midiprep System (Madison, WI). Purified RNA was concentrated by alcohol precipitation,
using 1 part purified RNA with 10% 3M sodium acetate, and 2 parts absolute EtOH. The mixture
was incubated on ice for 30 minutes, and then centrifuged at 16,000 X g for 30 minutes. The
supernatant was removed, and the pellet air-dried, then resuspended in diethylpyrocarbonate
(DEP C)-treated water to a volume of approximately 4 µg/µl.
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Spectrophotometric readings of RNA (A260), as well as sample purity readings (260
nm/280 nm) were obtained using the NanoDrop 2000 system (Thermo Fisher Scientific;
Chicago, IL). RNA was stored at -70⁰ C.

Electrophoresis

Horizontal agarose gels were run in the Owl B1A-BP 10 lanes gel rig (Thermoscientific;
Logan, UT). RNA integrity was verified by running a 1% agarose gel using agarose GP (MidSci;
St. Louis, MO) with 25 µl/1000 ml ethidium bromide (EtBr) added. 1 µl of purified RNA was
mixed with 2 µl 6X Blue/Orange loading dye (Promega; Madison, WI). 0.5% TAE running
buffer included 0.0001% EtBr. The gel was run at 75 V for 30 minutes, using 1:2:9 parts purified
RNA, loading dye, and Tris EDTA (TE), respectively.

Selection of Reference Genes

A reference gene is a gene expressed in all cells with the characteristics of constant
expression, similar abundance, no response to experimental treatment, and consistent expression
among donors or cell lines. Reference genes are used to normalize the set of parameters for
calculating qRT-PCR results. While previous history may indicate the efficacy of using a
specific reference gene, every experiment requires testing and evaluation within the performing
lab to verify the most reliable gene for that specific sampling set of parameters. Six genes were
selected from the literature that had been previously used successfully with HCC cell lines:
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hydroxymethylbilane synthase (HMBS), TATA-binding protein (TBP), hypoxanthine
phosphoribosyltransferase 1 (HPRT1), ribosomal protein L41 (RPL4-1), Splicing factor,
arginine/serine-rich 4 (SFRS4), and Beta-actin (ACTB). Using the standard deviation, HMBS
and TBP were selected as the two reference genes that had the least fluctuation in threshold cycle
(Ct) values among combined triplicate samples of five HCC cell lines: Hep G2, Hep 3B, Huh 7,
PLC-PRP 5, and SK Hep.

Quantitative Reverse Transcriptase-Real Time-Polymerase Chain Reaction (qRT-PCR)

qRT-PCR is defined as the collection of an increasing fluorescent signal for one or more
gene targets in real time during a polymerase chain reaction, leading to a quantitative value for
each target. The protocol was carried out per the Minimum Information for Publication of
Quantitative Real-Time PCR Experiments (MIQE) guidelines (Bustin et al., 2009). Briefly,
reverse-transcribed mRNA from each line was assessed for transporter expression using Taqman
probes (Applied Biosystems/Life Technologies, Grand Island, NY) and an Eppendorf
Realplex™ thermal cycler. Prepared cDNA was loaded into TempAssure PCR 0.2 ml thin-wall
opaque polypropylene strip tubes (USA Scientific, Ocala, FL) or white Thermo-Fast 96 detection
plates (Thermo Fisher Scientific, Chicago, IL). Taqman (Applied Biosystems; Carlsbad, CA)
hydrolysis chemistry: one part Taqman assay, which consists of a pair of unlabeled PCR primers
and a TaqMan® probe with a 6-carboxyfluorescein FAM™ dye at the 5’ end and a nonfluorescent minor groove binder (MGB) quencher dye, NFQ, at the 3’ end, specific to the target
gene of interest, 10 parts Taqman master mix (Lot #s 1111136, 1112139, 1202145, 1404201 and
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1612279), consisting of AmpliTaq Gold® DNA hot-start activation Polymerase, a blend of
dNTPs with dTTP⁄dUTP and Uracil-DNA Glycosylase (UDG) (to prevent mutagenesis by
eliminating uracil from DNA molecules), and a passive internal reference based on proprietary
ROX™ dye, 7 parts nuclease-free water, and 100 ng of cDNA to a total volume of 20 µl per
sample. qPCR was completed, using the Eppendorf ep Realplex2 Mastercycler, with program
settings at initial 90⁰ C for 10 minutes, followed by 40 cycles of 95⁰C denaturing temperature for
15 seconds, and 60⁰C annealing/extension temperature (for all primers) for 1:00 minute. Melting
curves were non-applicable with hydrolysis chemistry. Taqman protocol primers are designed to
give 95%-105% efficiency ("Amplification Efficiency of TaqMan Gene Expression Assays ",
2006). Four types of samples were prepared, all run in triplicate, as required for use with the
∆∆Ct method of calculating expression levels. The standard (control) was comprised of equal
amounts of cDNA from all 13 HCC cell lines: 1) Experimental sample + Target gene assay; 2)
Experimental sample + Reference gene assay; 3) Standard sample (control) + Target gene assay;
and 4) Standard sample (control) + Reference gene assay. The Comparative Ct Method, a.k.a. the
∆∆CT Method, was used to measure relative quantification, the expression-level change of a
target gene among different samples based on a given sample relative to an internal control
sample, as follows:
R=2 -∆∆CT =2-(∆CT sample - ∆CT calibrator)
=2 –

[(CT sample-CT reference gene)-(CT calibrator-CT reference gene)]

Assays from each of the thirteen HCC cell lines were run with the two reference genes,
TBP and HMBS, and the internal standard/control of equal amounts of the thirteen combined cell
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lines. To accurately average the two expression levels (R) resulting from calculations using two
control genes, the geometric mean was calculated to control for outlying values and abundance
differences among different genes (Vandesompele et al., 2002).

Western Blot Analysis

Analysis of protein expression was carried out by western blot analysis as previously
described (B. C. Fuchs, Finger, Onan, & Bode, 2007; B. C. Fuchs et al., 2004). Briefly, cultured
cells were harvested into a cell lysis buffer (2% SDS, 25 mM Tris, 1x protease inhibitors
(Halt™, Thermo Fisher Scientific, Chicago, IL), sonicated, and quantified for protein content on
a Nanodrop™ spectrophotometer. Equal amounts (20 µg) of protein were loaded into wells of 420% polyacrylamide gels (Bio-Rad, Hercules, CA), subjected to electrophoresis and transferred
to PVDF membranes (Millipore, Billerica, MA). Blots were incubated overnight at 4° C with
primary antibodies diluted in 4% bovine serum albumin in TBST (20 mM Tris pH 7.5, 140 mM
NaCl, 0.1% (v/v) Tween-20). Antibodies used were ASCT2 (rabbit polyclonal #D7C12, Cell
Signaling Technology, Danvers, MA); LAT1 (rabbit polyclonal #Ab685226, AbCam,
Cambridge, MA); COX IV (3E11) (Cell Signaling Technologies, Danvers, MA); and beta actin
(rabbit polyclonal #D6A8); - all from Cell Signaling Technology. After washes with TBST,
blots were incubated with horseradish peroxidase-linked goat-anti-rabbit IgG, washed four more
times, exposed to LumiGLO™ (Cell Signaling Technology) and visualized on a G:Box iChemi
XT (LFB) chemiluminescent imaging system (Syngene, Cambridge, England). Band intensities
were quantified by Image-J software.
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Amino Acid Transport Analysis

Amino acid transport studies were performed using the 24-well cluster tray technique
employed extensively by our laboratory in past studies (Bode et al., 2002; B. C. Fuchs et al.,
2007; B. C. Fuchs et al., 2004). Biochemicals used to distinguish glutamine transport activities
were: System A (SNAT 1, 2 and 4); N-(α-methylamino)-isobutyric acid (MeAIB); System N
(SNAT3, 5 and 7); L-Glutamic acid γ-monohydroxamate (GGH); aminooxyacetic acid (AOA);
and L-Aspartic acid γ-monohydroxamate (ABH); and System ASC (ASCT2): γ-L-Glutamyl-pnitroanilide Hydrochloride (GPNA). For System L – Na+-independent 2-aminobicyclo-(2,2,1)heptane-2-carboxylic acid (BCH)-inhibitable leucine transport activity was used; LAT1-selective
inhibitors, while recently reported (Oda et al., 2010; Wempe et al., 2012), are not yet
commercially available. Differences in transport rates were analyzed by Student’s t-test with p <
0.050 considered significant.

Spheroid studies

Cell lines were grown in monolayer format, using 4.5 mg/ml, High Glucose Dulbecco’s
Modified Eagle Medium, 1% antibiotic/antimycotic solution, and 10% triple 0.1 μM filtered fetal
bovine serum. Cells were grown in 25 cm2 Falcon T-flasks in a humidified incubator at 37o C
with 5% CO2. Cells were allowed to reach confluence (100% growth surface coverage). The
cells were then suspended in media, using TripLE Express dissociation enzyme, for two
purposes: 1) to harvest the RNA to make cDNA for testing monolayers; and 2) to transfer cells to
spinner flasks, with suspended stirring rods, to grow spheroids. The spheroids were grown via
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continual rotation of the spinner flasks containing 1 X 106 cells/ml suspended in 50 ml of
medium (see above) in a humidified incubator at 37o C with 5% CO2 until spheroids were visible
(> 1mm). The spheroids were harvested according to size: > 500 microns and < 500 microns.
RNA was extracted using Trizol medium, and then cDNA was prepared for use with qRT-PCR.

CHAPTER 3
RESULTS

Quantitative Reverse Transcriptase-Real Time-Polymerase Chain Reaction (qRT-PCR)

qRT-PCR was used to test relative amounts of nine transporters in 13 cell lines. There
was a comparative rise in expression level using both reference genes: if an expression level was
>1.000 (greater than the standard/control) with TBP, it was also >1.000 with HMBS, indicating
an appropriate selection of reference genes. The System ASC transporter, ASCT2, was
differentially expressed in all Group I (epithelial) and Group II (mesenchymal) HCC cell lines,
and the System L transporter, LAT1, was differentially expressed in all Group I cell lines except
for PLC/PRF 5, and in all Group II HCC cell lines except for SNU 423 (Figure 4). One or more
members of System A of the SLC 38 family of transporters (SNATs 1, 2, and 4) were expressed
in all Group I and Group II HCC cell lines (Figure 5). All cell lines, except for Hep G2,
expressed SNAT4. One or both System N members of the SLC38 family of transporters, SNATs
3 and 5, were differentially expressed in all Group I HCC cell lines except for PLC/PRF 5 and
Tong (see Table 1). A notable pattern in the Group II cell lines was the lack of expression of
SNAT3 and SNAT5 (Figure 6 and Table 2). This agrees with the literature that defines Group II
as de-differentiated (Lee & Thorgeirsson, 2002) thus no longer retaining features of normal
hepatocytes that generally use System N for glutamine uptake. However, a more recently
identified transporter, SNAT7, having an expression pattern and substrate profile with a high
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similarity to the known system N transporters (Hagglund et al., 2011), was expressed in all
Group II cell lines. While an earlier study revealed that SNAT7 was highly expressed in rat liver
(Sundberg et al., 2008), further studies had not been done to determine its presence in HCC.
These recent experiments verify that SNAT7 is expressed in the 13 HCC cell lines studied and,
given the significant quantitative expression in most of the Group II cell lines in comparison with
the control, it is the only System N transporter tested that continues to be expressed even upon
liver de-differentiation. However, the preferred substrates for SNAT 7 do not include glutamine
(Hagglund et al., 2011).
Expression of the System N transporters, SNAT3 and SNAT5, was widely variable
across the Group I cell lines, with a nearly five- and eight-fold increase over base line for SNAT
3 in Hep G2 and Huh 7, respectively, while there was a complete absence of expression in Tong.
For all 13 cell lines, the System N transporters, SNAT3 and SNAT5, were less prevalently
expressed than the System A transporters, SNATs 1,2 and 4 (Figures 5 and 6).
The System B0,+ transporter, ATB0,+, was expressed in three of the Group I HCC cell
lines only, Hep G2, Huh 7, and Hep 3B; and it was expressed in none of the Group II HCC cell
lines (Figure 7). Though ATB⁰,+ has been reported to be upregulated in tumors of epithelial
origin (Karunakaran et al., 2008), it was undetectable by Northern blotting in isolated human
hepatocytes and adult and fetal human liver (Bode et al., 2002). However, an hepatoblastoma
biopsy contained dramatically more ATB0,+ mRNA than the cell line, implicating significant
translational and posttranslational mechanisms.
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Figure 4. Results of transporter mRNA expression in Group I and II cell lines with ASCT2 and
LAT1 transporters. A) The System ASC transporter, ASCT2, and the System L transporter,
LAT1, was differentially expressed in all Group I cell lines except for PLC/PRF. B) ASCT2 was
also expressed in all Group II HCC cell lines, and LAT1 was expressed in all Group II HCC cell
lines except for SNU 423.
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Figure 5. Results of transporter mRNA expression in A) Group I and B) Group II cell lines with
System A of the SLC38 family of transporters, SNATs 1, 2, and 4. All cell lines showed an
expression level >1.000 for one of more of the transporters.
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Figure 6. Results of transporter mRNA expression in A) Group I and B) II cell lines with System
N of the SLC38 family of transporters, SNATs 3, 5, and 7. One or both System N members of
the SLC 38 family of transporters, SNATs 3 and 5, were differentially expressed in all the Group
I HCC cell lines except for PLC/PRF 5 and Tong; and neither were expressed in the Group II
HCC cell lines. Another System N transporter, SNAT 7, was differentially expressed in all
Group I and Group II HCC cell lines.
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Figure 7. System B0,+ transporter, ATB0,+ expression. A) Only three of the Group I HCC cell
lines expressed ATB0,+: Hep G2, Huh 7, and Hep 3B. B) ATB0,+ was not expressed in any of the
Group II HCC cell lines.
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Table 1
Summary of the Group I SLC38 (SNAT) family amino acid transporter usage across the six cell
lines tested. Group I shows a widely divergent range of transporters used, including the System
N transporters, SNAT3 and SNAT5, the usual route of glutamine transport in normal liver.
Group I

SLC38 (SNAT) Transporter Family

Cell Line

SNAT1 SNAT2 SNAT3 SNAT4 SNAT5 SNAT7
√

Hep G2
Huh 1

√

√

Huh 7

√

√

Hep 3B

√

PLC/PRF 5

√

√

Tong

√

√

√

√

√

√

√

√

√

√

√

√
√
√

√
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Table 2
Summary of the Group II SLC38 (SNAT) family amino acid transporter usage across the seven
cell lines tested. This group is notable for the lack of SNAT3 and SNAT5 transporters as these
cell lines exhibit a dedifferentiated phenotype that no longer has access to liver-specific
transporters.
Group II

SLC38 (SNAT) Transporter Family

Cell Line

SNAT1 SNAT2 SNAT3 SNAT4 SNAT5 SNAT7

SK Hep

√

√

√

Focus

√

√

√

SNU 449

√

√

√

√

SNU 475

√

√

√

√

√

√

√

SNU 387
SNU 423

√

Mahlavu

√

√

√
√

√

Western blot analysis

Antibodies for ASCT2 and LAT1 transporter protein have produced reliable and
consistent Western blot results for HCC protein studies. Western blot studies of the HCC cell
lines were completed by Evan Witke, undergraduate student at the time of completion. All Group
I results showed similar abundance of protein in comparison with mRNA per qRT-PCR, with the
most abundant expressers yielding the greatest amount of protein except for PLC/PRF which
indicated a greater abundance of protein in contrast to mRNA (Figures 8 and 10). LAT1 protein
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abundance for Group I differed from mRNA expression for both Huh 7 and Tong as both showed
greater amounts of protein than indicated when compared to the group as a whole. For all Group
I cell lines for LAT1, mRNA abundance was less than the abundance for ASCT2 per cell line,
except for Tong which showed a greater abundance of LAT1 protein than ASCT2.
Group II Western blot results for ASCT2 showed similar abundance of protein in
comparison with mRNA for five of the seven cell lines: SK Hep, SNU475, SNU387, SNU423,
and Mahlavu. Both Focus and SNU449 showed a greater abundance of LAT1 than ASCT2
mRNA with less abundance of protein (Figures 9 and 11).
ASCT2 protein expression for all 13 cell lines was greatly increased and/or
disproportionate in comparison with LAT1 per all mRNA results. In addition, there was no
universal comparison between mRNA abundance and protein levels per individual cell line,
often with a substantial margin of difference, e.g., Focus having less than half the mRNA
expression of ASCT2 compared to LAT1 yet showing greater than six times the abundance of
protein for LAT1.
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Figure 8. Western blot results showing differential expression of ASCT2 and LAT1 protein in
six Group I HCC cell lines. Twenty µg protein samples were used in 4-20% polyacrylamide gels,
with GAPDH as the loading control. (Western blot studies completed by Evan Witke.)

Figure 9. Western blot results showing differential expression of ASCT2 and LAT1 protein in
seven Group II HCC cell lines. Twenty µg protein samples were used in 4-20% polyacrylamide
gels, with GAPDH as the loading control. (Western blot studies completed by Evan Witke.)
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Western blot: ASCT2 and LAT1 with Group I HCC
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Figure 10. Comparison of protein expression levels of ASCT2 and LAT1 transporters in six
Group I HCC cell lines. ASCT2 results for showed similar abundance of protein in comparison
with mRNA per qRT-PCR, with the most abundant expressers yielding the greatest amount of
protein except in the case of PLC/PRF, which indicated a greater abundance of protein in
contrast to mRNA. LAT1 protein abundance differed from mRNA expression for Huh 7 and
Tong.
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Western blot: ASCT2 and LAT1 for Group II HCC
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Figure 11. Comparison of protein expression levels of ASCT2 and LAT1 transporters in seven
Group II HCC cell lines. Group II Western blot results for ASCT2 showed similar abundance of
protein in comparison with mRNA for five of the seven cell lines: SK Hep, SNU475, SNU387,
SNU423, and Mahlavu. Both Focus and SNU449 showed a greater abundance of LAT1 than
ASCT2 mRNA with less abundance of protein.

Transport Studies

Transport of Leucine and Glutamine in Group I and Group II

A higher rate of leucine compared to glutamine transport is universal in both the Group I
and Group II cell lines though most of the cell lines showed higher levels of mRNA for ASCT2
(the predominant transporter of glutamine) than for LAT1 (the predominant transporter of
leucine) via RT-qPCR analysis (Figures 12 and 13). As Western blot analysis of ASCT2 and
LAT1 revealed (Figures 9-12) protein abundance for ASCT2 was greater than for LAT1 in all
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cell lines, except for Mahlavu, and there was no universal comparison between mRNA
abundance and protein levels, most notably in Focus which showed less than half the mRNA
expression of ASCT2 compared to LAT1 yet with greater than six times the abundance of
protein for ASCT2. Yet both glutamine and leucine were transported in equivalent amounts in
the Focus cell line, indicating activity that was not predicted by either mRNA or protein
abundance. These results reveal complex distinctions among molecular biology, cell biology, and
physiology, with a discrepancy between transporter expression and activity.
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HCC Group I: 10 µM Gln and Leu Transport
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Figure 12. Initial-rate (30-second) transport in Group I cell lines. Using the radiolabeled amino
acids, L-[G-3H] glutamine or L-[G-3H] leucine, revealed a higher rate of leucine transport
compared to glutamine in all Group I cell lines.
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HCC Group II: 10 µM Gln and Leu Transport
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Figure 13. Initial-rate (30-second) transport in Group II cell lines. Using the radiolabeled amino
acids, L-[G-3H] glutamine or L-[G-3H] leucine, revealed a higher rate of leucine transport
compared to glutamine in all Group II cell lines. The range of variation included nearly
equivalent glutamine and leucine transport for Focus compared to a five-fold difference in the
SNU423 cell line.

Cis- and Trans-stimulators and Inhibitors

Stimulator and inhibitor studies serve to identify abundance of transporters in reference to
others by acting either as enhancers of specific transporter activity (e.g., aminooxyacetic acid as
a cis-stimulator of System N) or an inhibitor of function via competition for available
transporters (e.g., L-Glutamic acid γ-monohydroxamate (GGH). Cis-inhibition is effected
outside the cell membrane and trans-stimulation/inhibition is effected inside the cell membrane
(Figure 14). Results were equivocal for all stimulators and inhibitors tested.
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To further define the prevalence of ASCT2 for glutamine transport in HCC cell lines, two
cis-stimulators of System N, AOA and ABH, and one inhibitor of System N, GGH, were tested
at a concentration of 5 mM in glutamine transport with three Group I cell lines, Hep G2, Hep 3B,
and Huh 1; and with two Group II cell lines, SK Hep and SNU423 (Figures 15 and 16). In
studies using AOA, results were inconsistent, with an increase in glutamine transport in Hep 3B,
Sk Hep, and SNU423, and a decrease in glutamine transport in the remaining two cell lines, Hep
G2 and Huh1.
Contrary to the reported stimulatory activity of ABH, the results of ABH transport
showed a significant decrease in glutamine transport in all cell lines tested. On the other hand,
GGH significantly decreased glutamine transport, as expected, exhibiting a greater than 2-fold
decrease in the uptake of glutamine in all tested cell lines. Therefore, GGH inhibition showed
that ASCT2 and System A (SNATs 1, 2, and/or 4) are responsible for >60% of glutamine
transport.

Figure 14. Cell membrane indicating glutamine transport inhibition and stimulation. Cisinhibition is effected outside the cell membrane and trans-stimulation/inhibition is effected inside
the cell membrane.
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Glutamine transport (10 μM) with cis stimulators of System N:
AOA and ABH
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Figure 15. AOA and ABH as cis stimulators of System N. Of the five cell lines tested with AOA,
only three cell lines, Hep 3B, SK Hep, and SNU423, showed an increase in glutamine transport.
In contrast, ABH caused a significant decrease in glutamine transport in all five cell lines.
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Figure 16. GGH as an inhibitor of System N transporters. GGH inhibition resulted in a greater
than 2-fold decrease in the uptake of glutamine in all tested cell lines, indicating that SNATs 1,
2, and/or 4 are responsible for >60% of glutamine transport.

Competitive Inhibition Using the Amino Acid, Threonine

Competitive inhibition of glutamine transport using the small neutral amino acid,
threonine, indicated a minimal role of SNAT 4 in glutamine transport (Figure 17). Threonine is
not transported by ASCT2 or System N and only via SNAT1 in System A. Inhibition of ASCT2
with progressively increasing concentrations of threonine for Hep 3B and SK Hep showed a
steady decrease in glutamine transport except for an undefined increase in transport at 1.0 mM.
The near complete suppression of ASCT2 activity at 5 mM and higher levels of threonine
revealed the minimal expression of SNAT1 in glutamine transport for both Hep 3B and SK Hep.
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Glutamine transport (10 µM) with threonine as an inhibitor of
ASCT2
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Figure 17. Competitive inhibition of ASCT2 with threonine. Using progressively increasing
concentrations of threonine for Hep 3B and SK Hep showed a steady decrease in glutamine
transport except for an increase in transport at 1.0 mM. Threonine is not transported by System N
and only via SNAT1 in System A. The near complete suppression of ASCT2 activity at 5 mM
and higher levels of threonine reveals the minimal expression of SNAT1 in glutamine transport
for Hep 3B and SK Hep.

MeAIB and Glutamine Accumulation Studies

Transport activity studies with amino acids have traditionally been completed using 30
second exposure to a radioisotope. This assures that the uptake observed is due to accumulation
of free exchangeable amino acids (available for influx and efflux) versus amino acid
incorporation into macromolecules such as proteins and other amino acids (insoluble). New
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amino acid transport studies were designed, therefore, to reveal a profile of amino acid uptake
due to intercellular requirements for free amino acids (completed by Aparna Agarwal, Master’s
degree candidate). Over increasing increments of time the insoluble portion is expected to
represent an increasingly larger percentage of the total amount of glutamine transported (Figure
18). Results of transport studies, however, often appeared to contradict gene profiles as in the
case of the System A transporters, SNATs 1, 2, and 4. All thirteen HCC cell lines were positive
for differential amounts of one or more of the System A transporters (see Table 1), however,
transport studies with the glutamine analog, alpha-(methylamino)-isobutyric acid (MeAIB),
failed to provide consistent data. Numerous published studies had shown that MeAIB is a
substrate of System A yet most studies completed at our lab showed increased versus decreased
glutamine uptake across various conditions such as incubation on ice and at 37⁰C, as well as
after amino acid starvation. It was hypothesized that the System A transporters, having a lower
affinity for glutamine than ASCT2, failed to add measurable glutamine uptake during 30 second
exposure. New glutamine transport studies +/- MeAIB were completed using five time points
from 1- 120 minutes (Figures 19 and 20). Results showed that MeAIB inhibition in the HCC cell
lines was dependent on both time and the abundance of SNAT2 (see Table 3) versus the other
two System A transporters, with the lowest expressers of SNAT2, SNU475 and Mahlavu,
showing no inhibition across all time points, and the highest expresser of SNAT2, Hep G2,
showing ~40-50% decreased glutamine transport at all time points.
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Concept graph: glutamine (10 µM) free vs. incorporated
amino acid
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Figure 18. Concept graph showing expected glutamine transport over time. Over 120 minutes an
increasing amount of glutamine is expected to be incorporated into macromolecules.
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Transport study: Glutamine (10 µm) accumulation in
1-120 minutes
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Figure 19. Glutamine accumulation transport study in six HCC cell lines. Glutamine uptake
increased over time due to a combination of free exchangeable glutamine accumulation and
glutamine incorporation into macromolecules such as proteins. (Transport studies completed by
Aparna Agarwal.)

46

Transport of glutamine (10 µM) +/- System A inhibitor,
MeAIB
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Figure 20. Accumulation versus incorporation study of glutamine transport. Results showed that
System A inhibitor, MeAIB, was effective only in cell lines with the greatest abundance of
SNAT2, SNU449 and Hep G2, compared to the other cell lines tested, without reference to the
other two System A transporters, SNAT1 and SNAT4. (Transport studies completed by Aparna
Agarwal.)
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Table 3
Order of System A transporters based on abundance of mRNA per qRT-PCR tests.
SLC38 System A transporters

mRNA Expression Values

Low to high abundance

Names
SNAT1
SNAT2
Mahlavu SNU475
SNU475 Mahl
Huh7
Huh7
Hep G2
Huh1
Huh1
SNU449
SNU449 Hep G2

SNAT4
Mahlavu
SNU475
SNU449
Hep G2
Huh1
Huh7

Substrate Inhibition

Further results showing the primacy of the ASCT2 transporter in HCC cell lines were
revealed from a study using lithium as the substrate instead of sodium (Figure 21). While System
N tolerates lithium as the cation for transport, ASCT2 does not, and the comparison between
sodium and lithium transport of four cell lines, Hep G2, Hep 3B, PLC/PRF 5, and SK Hep,
indicated near complete elimination of glutamine transport in the lithium substrate. Reports
differ regarding System A and lithium, however, with an older study stating that the
effectiveness of the two cations varies over fivefold (Christensen & Handlogten, 1977) and a
recent study stating that Li+ can, indeed, substitute for Na+ in driving transport though its
effectiveness as a replacement for Na+ depends on membrane potential and varies with
parameters such as Vmax (Mackenzie et al., 2003).
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Figure 21. Glutamine transport as a function of substrate. Glutamine transport was significantly
decreased with the use of lithium versus sodium as the transport cation, indicating that ASCT2 is
the primary transporter of glutamine.

Chloride-free Transport Effects on ATB0,+

RT-qPCR results showed expression of ATB0,+ in three of the Group I cell lines, Hep G2,
Hep 3B, and Huh7, and in none of the Group II cell lines. This transporter requires the cotransport of Na+ and Cl- in the same direction, therefore, a glutamine transport study was
completed using the three Group I ATB0,+ positive cell lines with Na+ +/- Cl- to determine if the
cellular activity was equivalent to transporter mRNA expression. Focus, a Group II HCC cell
line that was negative for ATB0,+ , was used as a control (Figure 22). The results showed that all
the cell lines tested had reduced glutamine uptake in the presence of Cl--free media, with the
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greatest reduction in the non-expressing cell line, Focus. This indicated a greater role for chloride
in the transport process such as maintaining the electrogenic forces needed to drive transport,
therefore, it proved to be an unreliable test for discriminating the presence of ATB0,+. To clarify
which transporters were involved in Cl--free media transport, the same cell lines were used to test
transport of 10 µM arginine (Arg) +/- BCH to block possible cationic and neutral amino acid
transporters of the SLC7 family (SLC7A5-11), which includes System y(+)L, obligatory
exchangers of cationic amino acids (sodium-independent) and neutral amino acids (sodiumdependent), including glutamine (Figure 23). Co-transport of Na+ was observed only for the
y(+)L transporters when they carry neutral amino acids. The question posed was whether
glutamine was binding to the active site of ATB0,+ depending on the presence of Na+. The results
showed arginine transport that was largely Na+-independent in all cell lines but with a widely
variable Na+-dependent component upon inhibition with BCH: Focus—32%; Hep G2—8%; Hep
3B—3%; and with no significant Na+-dependent component with Huh7. Therefore, variable
though minimal transport can be assigned to System y(+)L in Focus, Hep G2, and Hep 3B.
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Figure 22. Na+-dependent vs. Cl--free Na+-dependent 10 µM glutamine transport in HCC cell
lines expressing ATB0,+. All cell lines, including Focus, the non-expressing control, showed
reduced glutamine transport, indicating a greater role for chloride in the transport process.
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Transport of arginine (10 µM) +/- BCH in HCC cells expressing
mRNA for ATB0,+
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Figure 23. Transport of 10 µM arginine +/- BCH in HCC cells expressing mRNA for ATB0,+.
Results showed Arg transport was largely Na+-independent in all cell lines.

pH Sensitivity Transport Studies

ASCT2 is a relatively non-pH-sensitive transporter, therefore, adjusting pH from an
optimal 7.6 reveals the input from pH-sensitive Systems A and N. Transport of glutamine for
two HCC cell lines, Hep 3B, representing Group I, and SK Hep, representing Group II, were
tested using three additional pH levels (Figure 24). At a pH of 6, both cell lines transported
roughly half the glutamine in comparison with the control, and at pH 7, glutamine transport
dropped to ~75% for Hep 3B with little change for SK Hep. At pH 8, however, Hep 3B showed
~15% decrease while SK Hep showed ~15% increase in glutamine transport compared to the
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optimal 7.6 pH. These variations may be explained by the optimal pH conditions of each of the
System A transporters: SNAT1—7.4; SNAT2—8.0; and SNAT4—8.5. For System N, pH range
was not available for SNAT3, however, SNAT5 has an optimal range of sensitivity between 7.0
and 8.0 pH (Zhang, Zander, & Grewer, 2011); (Sugawara et al., 2000); (Glutamine in Clinical
Nutrition, 2015). Given the optimal pH of SNAT2, the decrease in glutamine transport at a pH of
8 may denote less SNAT2 activity in Hep 3B versus an increase in SNAT2 activity in SK Hep.
An increase in SNAT4 activity may also be represented at pH 8 as the optimal pH of 8.5 is
approached. SNAT1 is best represented with the control and SNAT5 will be well represented at
all levels except pH 6. The clearest result is the reduction of glutamine transport at pH 6 which
supports ASCT2 as the primary glutamine transporter with up to 50% of transport provided via
various transporters of Systems A and N.
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Figure 24. pH sensitive System A and System N glutamine transporters vs. non-pH sensitive
ASCT2. Adjusting the pH from an optimal 7.6 revealed the transporter preference of the two cell
lines, Hep 3B and SK Hep. There was a measurable decrease in glutamine transport at lower pH
values of 6 and 7 for both cell lines. At pH 8, however, Hep 3B showed a decrease while SK Hep
showed an increase in glutamine transport. These differences highlight variable transporter
abundance among different cell lines.

Spheroid studies

Spheroid studies were undertaken to mimic the initial avascular growth stage of a tumor
and to provide a system of intermediate complexity between a monoculture and tumors in vivo
Figure 25). Though full tissue interaction among tumor and stromal cells and their respective
transporters are not present in spheroid models, there are regions of hypoxia, increased acidity,
and nutrient limitation present at the spheroid center that may induce increased transcription of
amino acid transporters to support growth and proliferation under stress. The three cell lines in
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the study—two from Group I: Hep G2 and Huh 7; and one from Group II: SK Hep— were
harvested by size: < 500 microns and > 500 microns, with results showing a wide range of
mRNA expression levels for seven glutamine transporters. There was no significant difference
in ASCT2 //for both SK Hep and Hep G2 between the small and large spheroids, while there was
no expression of ASCT2 in Huh 7 in the smaller spheroid (Figure 26). For LAT1, SK Hep had
equivalent expression between the two sizes while Hep G2 only showed LAT1 expression at
>500 microns, and Huh 7 did not express LAT1 at either size. Further testing included System A
of the SLC38 family of transporters, indicating equivalent expression of SNAT1 and SNAT2 in
both spheroid sizes of SK Hep, respectively, but SK Hep did not express SNAT4, also absent in
monolayer studies (Figure 27). The greatest increase in System A expression was seen with
SNAT2 in Hep G2, with expression levels of 20.7 for spheroids <500 microns and 67.4 for >500
microns. SNAT2 was originally cloned from this cell line and it has been shown that a
physiological condition such as starvation may modulate expression of this transporter, though
there was no general increase in all three cell lines tested (Hatanaka et al., 2000). For
comparison, Hep G2 also showed a greater abundance of SNAT2 mRNA than most of the other
13 cell lines tested. Hep G2 also expressed SNAT1 in both spheroid sizes but with a slightly
higher expression level for <500 microns, and it did not express SNAT4 in either size. Huh 7
had variable results across the three members of System A, with SNAT1 and SNAT2 expressed
only in the larger spheroid, however, SNAT4 was expressed at a 12.4 expression level for the
>500 micron spheroids, substantially more than the expression level of 4.4 for the smaller
spheroids. This result could be predicted as Huh7 had also shown the highest level of SNAT4 in
qRT-PCR studies of the 13 cell lines in monolayers. The final set of transporters tested was
SNATS 3 and 5 from System N of the SLC38 family of transporters (Figure 28). Whereas
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System N is not expressed in Group II cell lines when tested in monolayers, SK Hep showed
minimal expression of SNAT3 in both spheroid sizes, and had no SNAT5 expression. Reversion
to a transporter that was unavailable to a mesenchymal cell line during monolayer growth may
indicate a change in the cell’s physiology to sustain tumor growth during stress. Hep G2 had
SNAT3 expression levels of 3.3 and 10.2 for spheroids <500 microns and >500 microns,
respectively, and only minimal expression of SNAT5 though both System N transporters were
expressed nearly equally via qRT-PCR monolayer studies. As a Group I cell line that maintains
liver specific characteristics, Hep G2 has normal access to System N transporters yet Huh7, also
a Group I cell line, showed no SNAT3 expression though it showed the highest expression level
of SNAT3 mRNA of all HCC cell lines tested. It also showed minimal expression of SNAT5
which had not been expressed via qRT-PCR studies. The results of the spheroid experiments
highlight the variability of transporter expression in each cell line which was not predicted by
mRNA abundance.

Figure 25. Micrographs of three spheroid populations grown from monolayer cell cultures: SK
Hep, Hep G2, and Huh7. Transporter abundance was tested via qRT-PCR in populations <500
microns and >500 microns.
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Figure 26. qPCR tests compared ASCT2 and LAT1 transporter expression among monolayers
and spheroids at <500 microns and >500 microns in size. ASCT2 was relatively stable in
abundance across all growth levels except absent in Huh7 at <500 microns, whereas LAT1
showed low abundance in SK Hep and Hep G2, and no expression in Huh 7.
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Figure 27. qPCR tests compared System A transporter expression among monolayers and
spheroids at <500 microns and >500 microns in size. Results showed minimal change in SNAT1
levels across all growth levels for SK Hep and Hep G2, and a great decrease at >500 microns for
Huh 7. SNAT2 transporter levels were stable in abundance for SK Hep, minimally expressed in
Huh 7, and dramatically increased in both the small and large spheroids in Hep G2. SNAT4 was
not expressed in either SK Hep or Hep G2, but was abundant in Huh 7.
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Figure 28. qPCR tests compared System N transporter expression among monolayers and
spheroids at <500 microns and >500 microns in size. Results for SNAT3 showed variable results
across growth levels per cell line: no change for SK Hep; progressively increasing amounts for
Hep G2; and a decreasing amount for <500 microns followed by a return to the monolayer level
of transporter expression for Huh 7. SNAT5 was not expressed in SK Hep and was low but
stable in abundance in Hep G2 and Huh 7.

Liver Tissue Samples

Two sets of liver tissue samples, denoted as 5125C (cancerous) and 5125N (normal), and
5533C and 5533N from two resected livers were analyzed for ASCT2 and LAT1 with Western
blots (Figures 29 and 30). Each set included one sample from HCC cancerous tissue and one
from tissue adjacent to the morphologically distinct cancer tissue. Electrophoresis gel tests
revealed degraded RNA, therefore, qRT-PCR testing for transporter expression could not be
completed. Western blots were performed in the interest of determining the presence of ASCT2
and LAT1 protein as well as whether adjacent non-tumorous cells played a greater or lesser role
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in supplying nutrients to the tumor (Guido et al., 2012). The results were inconclusive. In the
cancerous samples, the first set revealed a band for non-glycosylated ASCT2 only while the
second set revealed bands for both glycosylated and unglycosylated ASCT2. Glycosylation of
ASCT2 is required for trafficking to the membrane (Console, Scalise, Tarmakova, Coe, &
Indiveri, 2015). Both non-cancerous samples had equivalent bands for glycosylated ASCT2 and
the first sample, in contrast to the second, showed a more prominent band for unglycosylated
ASCT2. LAT1 also presented conflicting results; only the second tissue sample set produced a
band for the cancerous sample while both normal tissue samples produced faint bands. Sample
quality was likely the limiting factor for obtaining reliable results as the protein may have been
degraded, therefore, it could not be determined which sample type was positive for the greater
amount of transporter protein.

Figure 29. The four samples tested for ASCT2 transporter protein included two from resected
liver tumors (5125C and 5533C) and two from tissue adjacent to the tumor tissue (5125N and
5533C). Bands for glycosylated ASCT2 were present for one tumor sample and two adjacent
tissue samples, whereas bands for unglycosylated ASCT2 were present at different densities for
all four samples.
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Figure 30. Western blot results of liver tissue samples using LAT1 antibody. The four samples
tested for LAT1 transporter protein included two from resected liver tumors (5125C and 5533C)
and two from tissue adjacent to the tumor tissue (5125N and 5533C). Bands were present for one
tumor sample and two adjacent tissue samples.

CHAPTER 4
DISCUSSION

As the two amino acid transporters, ASCT2 and LAT1, have emerged as primary
glutamine transporters in a wide range of cancers (DeBerardinis & Cheng, 2010) (Hensley et al.,
2013), additional glutamine transporter families, specifically, SLC38 (the SNAT family,
SLC38A1-5, 7); and SLC6A14 (ATB0,+) must be recognized as supportive in both major and
minor roles in human HCC. These studies were undertaken to assess three elements: 1) the
ubiquity of ASCT2 and LAT1 expression in epithelial and mesenchymal human HCC cells –
modeling primary and metastatic carcinoma, respectively; 2) the array of glutamine transporters
expressed in addition to ASCT2; and 3) the extent to which each transporter contributes to
glutamine uptake in human HCC cell lines.
The System ASC transporter, ASCT2, was differentially expressed in all six of the Group
I (epithelial) cell lines as well as in the seven Group II (mesenchymal) cell lines (Figure 5). The
System L transporter, LAT1, was differentially expressed in all but the cell line PLC/PRF 5 in
Group I, and in all of Group II except for SNU423. While it was expected that these two
transporters worked in concert with each other—ASCT2 transporting glutamine into the cell and
LAT1 transporting glutamine out of the cell in order to import essential amino acids (Fuchs &
Bode, 2005)—mRNA expression for ASCT2 was relatively closely related to its corresponding
protein expression, while LAT1 did not show an overall correlation between mRNA profile and
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protein abundance. Furthermore, neither mRNA nor protein abundance were correlated with
cognate activities via transport studies, with the most striking discrepancy in the Focus cell line
which expressed less than half the mRNA expression of ASCT2 compared to LAT1 while
yielding greater than six times the abundance of protein for LAT1 by Western blot. Yet both
glutamine and leucine were transported in equivalent amounts in the Focus cell line.
Original studies defining System ASC per the preferred substrates of alanine, serine, and
cysteine have been revised by a study in 2015 that revealed cysteine to be a potent competitive
inhibitor of ASCT2 but not a substrate (Scalise, Pochini, Pingitore, Hedfalk, & Indiveri, 2015).
Furthermore, the binding of cysteine to a secondary site on the transporter triggered
unidirectional glutamine efflux not only in vitro but in vivo. It was hypothesized that increased
levels of extracellular cysteine may be a cue for release of intracellular substrates of ASCT2 for
undetermined metabolic or signaling purposes. Information about the additional functions of
transporters such as ASCT2 and SNAT2 (below) provide necessary information on transporter
activities that may subvert chemotherapeutic applications.
System A of the SLC38 family of transporters was universally expressed via qRT-PCR
studies in all 13 cell lines tested, however, an unexpected result of System N studies was the
expression of a more recently-defined member, SNAT7. It was expected that the Group II cell
lines, as dedifferentiated and mesenchymal HCC cell types, would not express SNAT3 or
SNAT5, transporters of glutamine present in normal liver, and the expectation was extended to
SNAT7. However, the inclusion of SNAT7 in all Group 2 results describes a supplemental route
of glutamine transport that had previously been unknown (Sundberg et al., 2008), and the
conclusion that System N does not operate in Group 2 cell lines must be modified.
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The evidence of the widespread use of System B0,+ transporter, ATB0,+, member 14 of the
SLC6 family of transporters, as a glutamine transporter in tumors of epithelial origin (Bhutia,
2014) had prompted studies to determine its presence in HCC cell lines. Only a portion of Group
1 and none of Group 2 cell lines used this transporter to supply glutamine. As various amino
acid-based prodrugs also serve as substrates for SLC6A14, it was important to delineate the
proportion of Na+ +/- Cl- transport in comparison with Na+-independent transport to reveal yet
another route of glutamine transport: System y(+)L. The widely variable evidence of Na+dependent transport, from 32% for the Focus cell line to 0% for the Huh7 cell line, emphasized
the importance of defining the available transporters prior to chemotherapeutic protocols.
Studies using various inhibitors, substrates, and pH variables consistently showed ASCT2
to be the major transporter of glutamine, though pH studies revealed additional glutamine
transporters that could also sustain the metabolic economy, including Systems A and N. Studies
using the System A inhibitor, MeAIB, did not provide adequate results until glutamine transport
accumulation studies clarified that SNAT2 was the key transporter inhibited by MeAIB. A study
by Ling et al (2001) revealed that although MeAIB is a non-metabolizable amino acid, it
regulates the expression of SNAT2 by binding and translocating the substrate. The in vivo
adaptive response to intracellular amino acid depletion induces the transport activity of SNAT2,
a two-step process involving recruitment of preformed transporter protein from an intracellular
pool to the plasma membrane followed by activation of the transporter gene. Studies with
MeAIB, therefore, do not directly reveal abundance of transporter but the regulation of both
SNAT2 protein and gene, however, the greater abundance of SNAT2 mRNA in Hep G2
compared with five other HCC cell lines resulted in the greatest reduction in glutamine transport.
This indicated a greater amount of preformed SNAT2 protein during the tested transport time
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and, due to the act of substrate binding and translocation, possibly involved a conformational
change in the protein that influenced other signaling molecules inside the cell. Results of
accumulation studies with MeAIB may also inform the equivocal results for the other stimulators
and inhibitors tested as initial rate uptake may not have been sufficient for obtaining expected
results.
Spheroid studies also exemplified the complexity of transporter utilization, providing
insight into the intermediate complexity between a monoculture and a tumor. Regions of
hypoxia, increased acidity, and nutrient limitation at the spheroid center were predicted to
increase induction of ASCT2 as it has a Km of 50-100 µM, allowing it to take up glutamine more
efficiently at low ambient concentrations (Kanai & Hediger, 2003) in comparison with SNAT1
and SNAT2 with Km values of 498 mM, and 1.65 mM, respectively (Yao et al., 2000), and the
Km for System N (SNAT3 and SNAT5) amino acid transporters at ~1mM (Baird et al., 2004).
However, while previous studies have shown ASCT2 to be the main transporter of glutamine
during cell transformation (Fuchs & Bode, 2005) including a 10-fold increase in glutamine
uptake in HCC via ASCT2 (Bode et al., 2002), mRNA abundance of System A transporters,
SNATs 1, 2, and 4, as well as the System N transporter, SNAT 3, was greatly increased
compared to the abundance of ASCT2. While ASCT2 and LAT1 expression stabilized or
diminished among the three cell lines tested, SNAT2 expression was overwhelmingly increased
in the Hep G2 cell line. The dramatic difference between the increase in Hep G2 and the lack of
expression in both SK Hep and Huh7 may be explained in several ways. While SNAT2 is a
ubiquitously-expressed System A transporter, it is upregulated in response to amino acid
starvation or in hypertonic conditions, with both conditions presumably present in a spheroid
(Mackenzie & Erickson, 2004). However, SNAT2 is also a transceptor, a transporter that doubles
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as a receptor that functions to activate an intracellular signaling cascade (Hundal & Taylor,
2009) (Kriel, Haesendonckx, Rubio-Texeira, Van Zeebroeck, & Thevelein, 2011). Whereas it
could be expected that all three cell lines would upregulate SNAT2 under similar conditions, one
major difference among them is that only Hep G2 bears a mutation of beta-catenin, the protein
involved in cell signaling as an essential part of the WNT signaling pathway ("CTNNB1 gene,").
Beta-catenin mutated HCC cells are more sensitive to glutamine depletion (Tardito et al., 2011).
Transporter gene expression, in this case, was possibly dependent on the signaling cascade
evoked by the mutation. However, spheroids are only a model of tumor growth using cell lines,
therefore, extrapolation to transporter expression and activity in tumors can only be an estimate.
It was also seen via transport studies that mRNA expression did not directly correlate with either
protein levels or transport activity.
Previous RT-PCR analysis of liver biopsies that compared cirrhosis and HCC showed
that ASCT2 mRNA was more abundant in the fibrous noncancerous tissue than in the tumor
(Bode et al., 2002), however, our current samples could not corroborate this finding due to
sample degradation.
In the context of what is currently known about amino acid transporters and the
hypotheses tested, the complete group of studies reviewed above indicated there are many layers
of complexity in transporter trafficking as well as activity. It is necessary for transporters to
migrate to the cell membrane from the interior of the cell or to be made de novo. Amino acid
transporters may be glycosylated, with the sugars acting as ligands for receptors on the cell
surface to mediate cell attachment or to stimulate signal transduction pathways (Wormald, 2002).
Glycosylation can be essential in two ways. First, while non-glycosylated SNAT1 transporters
could migrate to the membrane in an equivalent time compared with glycosylated transporters,
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glutamine transport was shown to be significantly compromised in both glycosylation-impaired
mutants and deglycosylated SNAT1 (Iyer, Gu, & Jiang, 2016). In contrast, a study of ASCT2
showed that lack of glycosylation affected the amount of protein reaching the cell surface but not
the intrinsic transport activity (Console et al., 2015). Cancer cells typically exhibit altered
patterns of ASCT2 glycosylation, and these aberrations can promote invasive behavior and
tumor progression (Christiansen et al., 2014). Therefore, a transporter in one cancer may be
structurally distinct from the same transporter in another cancer.
Electrochemical status, an ever-shifting parameter, will also affect transporter activity.
All members of System A, SNATs 1, 2 and 4, are associated with depolarization of the
membrane potential, making the process electrogenic, and they rely on voltage dependent
binding of Na+ (Mackenzie et al., 2003). SNATs 3 and 5, alternatively, mediate Na+-coupled
movement of neutral amino acids in exchange for H+, and are thus electroneutral. These two
transporters will mediate the influx or efflux of glutamine depending on the intracellular
concentration. Of importance is the concentration of free ions available for exchange (those not
in the ER, etc.) The pH of the tumor environment may also vary as anabolic processes fluctuate
between glycolysis and aerobic respiration, and this will influence the type and number of amino
acid glutamine transporters operating at any given time (Baird et al., 2006).
All data results indicate that there are complex distinctions among molecular biology, cell
biology, and physiology. There may also be a discrepancy between transporter expression and
activity. Different cells traffic different amounts of transporters to the membranes depending on
ion pumps, transmembrane substrate gradients, transporter structural variations, and
electrochemical status. It must be concluded that none of the ascribed experimental protocols
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either alone or in combination have fully described the relationships among molecular biology,
cell biology, and physiology in HCC.

PART II
CHAPTER 5
INTRODUCTION

Glutamine Transporters

In vitro studies of glutamine transporters in cultured tumor-derived cells (see Part I)
provide only a partial understanding of transporter activity due to the known interaction of tumor
and stroma in the influx and efflux of nutrients in the process of tumor growth. Results from
previous studies show that growth-supporting glutamine transport in various tumors, including
breast cancer, occurs in both the carcinoma cells and its adjacent stroma (Martinez-Outschoorn et
al., 2011) Yet little is known regarding how tumors differentially express glutamine transporters
in carcinoma and stromal cells, establishing and supporting unique glutamine metabolic
economies. Also, the heterogeneity of tumors in vivo introduces variables that cannot be
simulated using cell lines alone, one of the reasons that many therapies that work in a culture
dish fail in pre-clinical and clinical trials. An animal model can demonstrate both the disease and
the biological processes pertaining to glutamine transport which could not be investigated
directly in humans for ethical reasons. Cell sorting techniques after tumor extraction can help to
differentiate transporter abundance among the cell types. The following studies were designed

69

using the BALB/c mouse and the EMT6 murine mammary carcinoma cell line that is syngeneic
(genetically and immunologically identical) to the BALB/c to provide insights into the evolution
of glutamine metabolic economies in vivo and to identify unique tumor transporter expression
patterns that might be harnessed for therapy or diagnosis.

Breast Cancer

Breast cancer is the most common cancer among American women, except for skin
cancers ("Trends in breast cancer deaths," 2017). About 1 in 8 (12%) women in the US will
develop invasive breast cancer during their lifetime. It is also the second leading cause of cancer
in women, with only lung cancer killing more women each year. The chance that a woman will
die from breast cancer is about 1 in 37 (about 2.7%).
The American Cancer Society's estimates for breast cancer in the United States for 2016 are
("U.S. Breast Cancer Statistics," 2017):


About 252,710 new cases of invasive breast cancer will be diagnosed in women.



About 63,410 new cases of carcinoma in situ (CIS) will be diagnosed (CIS is noninvasive and is the earliest form of breast cancer).



About 40,610 women will die from breast cancer.

Breast cancer is also the most common cancer in women worldwide. It is estimated that
more than 1.7 million new cases of breast cancer occurred among women worldwide in 2012
(most recent data available) (Laronga C, 2016).
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Breast cancer incidence rates around the world vary a great deal. In general, developed
countries (such as the U.S., England and Australia) have higher rates than developing countries
(such as Cambodia, Nepal and Rwanda) ("Breast cancer statistics," 2015), however, breast
cancer is the most common cause of cancer mortality among women in developing countries
("GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in
2012,"). The reasons for this are unknown but it is hypothesized that lifestyle and reproductive
factors play a large role ("U.S. Breast Cancer Statistics," 2017). Other variables include race,
ethnicity, and poverty ("Cancer Facts & Figures 2015," 2015). According to the World Cancer
Research Fund ("Breast cancer statistics," 2015), in Western Europe, area of the highest
incidence of breast cancer, Belgium had the highest rate followed by Denmark and France. By
continent and region, the highest incidence of breast cancer was in Northern America and
Oceania; and the lowest incidence in Asia and Africa.
Death rates from breast cancer have been declining since about 1989, with larger
decreases in women younger than 50 ("Trends in breast cancer deaths," 2017). These decreases
are believed to be the result of earlier detection through screening and increased awareness, as
well as improved treatment. Only about 5-15% of breast cancers are linked to inherited gene
mutations.

Breast Morphology and Cancer

The breast is composed of adipose, epithelial, and fibrous tissue. Each breast is organized
into 15– 25 lobes that are associated with 5–10 ducts that open at the surface of the nipple
("Breast," 2016) (Figure 31). The ducts are lined with squamous epithelium in the superficial
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portion that changes to a glandular, columnar, or cuboidal epithelium ("Cancer Stat Facts:
Female Breast Cancer," 2016). Most primary breast cancers are adenocarcinomas (neoplasia of
epithelial tissue with glandular origin characteristics, or both). These carcinomas are further
classified as in situ (noninvasive) or invasive. In situ breast carcinomas present with malignant
epithelial cells within the ducts or lobules, however, there is no extension beyond the basement
membrane. They are described either as ductal carcinoma in situ (DCIS) or lobular carcinoma in
situ (LCIS). Invasive breast carcinomas extend beyond the basement membrane and may
continue through the breast tissue with possible metastasis into regional lymph nodes or distant
sites.

Figure 31. Human female breast morphology. Inside a woman's breast are 15 to 20 sections
called lobes. Each lobe is made of many smaller sections called lobules. Fibrous tissue and fat

72

fill the spaces between the lobules and ducts (thin tubes that connect the lobes and nipples).
Tumors may be cancerous (malignant) or not cancerous (benign) ("Breast," 2016). (Reprinted
with permission.)

Major Molecular Breast Cancer Subtypes

Human breast cancer is typically divided into four major molecular subtypes: luminal A,
luminal B, HER2, and triple-negative/basal-like ("Molecular Subtypes of Breast Cancer," 2016).
Luminal tumors are those that begin in the inner cells lining the mammary ducts. About 30-70
percent of breast cancers are luminal A tumors. Their combined characteristics include: 1)
estrogen receptor-positive (ER positive); 2) Human Epidermal Growth Factor Receptor 2negative (HER2 negative); and 3) tumor grade 1 or 2. Luminal A tumors usually have the best
prognosis, with fairly high survival rates and fairly low recurrence rates (Voduc et al., 2010);
(Foukakis T, 2016); (Carey LA, 2014); (Arvold et al., 2011); (Metzger-Filho et al., 2013). [4143,46-47]. Luminal B tumors are usually ER positive but may be either HER2-positive or
negative. About 10-20 percent of tumors fall in this category, with good survival rates. HER2
type tumors may be HER2-positive or HER2-negative; HER2 type tumors comprise 5-15 percent
of breast tumors, and those that are HER2-positive can be treated effectively. Basal-like tumors
have cells with similar morphology to those of the outer (basal) cells surrounding the mammary
ducts and are difficult to treat, more biologically aggressive, and often present with a poor
prognosis.
About 15-20 percent of breast cancers are triple negative/basal-like (Fan et al., 2006);
(Voduc et al., 2010); (Foukakis T, 2016). (Howlader et al., 2014); (Kohler et al., 2015) with
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higher incidence in younger women, African-American women, and Hispanic women (Howlader
et al., 2014); (Sineshaw et al., 2014). Approximately 90 percent of basal-type cancers are truly
triple-negative, with a lack of hormone receptors on cancer cells and the absence of HER2
overproduction ("Breast Cancer Genetic Types," 2016). The 10 percent of basal-type cancers that
are not truly triple-negative do have some degree of hormone positivity. Approximately 90
percent of women with a BRCA1 gene mutation who develop breast cancer are affected by the
triple-negative type. As triple-negative breast cancers do not respond to hormone therapies they
are generally treated with a combination of surgery, radiation therapy, and chemotherapy.
Pertinent to this study was the finding that basal-like triple negative breast cancer cell growth is
dependent on glutamine uptake via ASCT2 activity compared with having minimal effects in
luminal breast cancer cells. Only basal-like triple negative breast cancer cells require ASCT2mediated uptake of glutamine to sustain mTORC1 signaling, cell growth and cell cycle
progression (van Geldermalsen et al., 2016). A previous study using high stringency Northern
hybridization analysis with an ASCT2 probe revealed ASCT2 expression in adipose mouse
tissue (Utsunomiya-Tate, Endou, & Kanai, 1996). It was, therefore, predicted that ASCT2 would
be present in the murine mammary fat pads.
Inherited breast cancer has been associated with germline mutations in genes that are
functionally involved in the DNA homologous recombination repair (HRR) pathway, including
BRCA1 and BRCA2 which serve as tumor suppressor genes (Le Calvez-Kelm et al., 2012). Most
BRCA1-related breast cancers are both triple negative and basal-like (Carey LA, 2014); (Atchley
et al., 2008); (Hartman et al., 2012); (Couch et al., 2015).
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Amino Acid Transporters in Breast Cancer

Information is incomplete for the glutamine transporters predicted and/or experimentally
determined in breast cancers. For the BALB/c mouse, The National Center for Biotechnology
Information (NCBI) gene database ("BALB/c genes," 2017) fails to mention one of the most
prominent transporters utilized in glutamine-dependent breast cancers, ASCT2. Another source
of predicted transporter expression, specifically in human cancerous tissue, The Human Protein
Atlas ("The Human Protein Atlas,"), predicted five of the eight glutamine transporters that tested
positive for mRNA in the mouse studies, indicating some homology across species (see Table 4).
This study seeks to broaden the understanding of the wide range of glutamine and other
transporters that may be utilized in the process of tissue transformation as seen in both a cell line
and a mouse model.
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Table 4
Results of human tissue proteome studies of human mammary carcinoma indicate the
presence of eleven out of nineteen transporters tested for this study ("Cancer Atlas," 2017).
Predicted membrane transporters
Cancerous tissue
Neg.
ASCT2

SLC1A5

SLC7A5

SLC7A5

y+LAT2

SLC7A6

O+

High
1 of 11

Med.

Normal tissue
Low

Neg.

Med.

Low

X

1 of 11

5 of 12

5 of 12

X

1 of 11

X
X

ATB

SLC6A14

SBAT1

SLC6A15

X

X

B0AT3

SLC6A18

X

X

B0AT1

SLC6A19

X

X

CAT4

SLC7A4

X

X

y+LAT1

SLC7A7

X

X

xCT

SLC7A11

unavailable

SNAT1

SLC38A1

SNAT2

SLC38A2

SNAT3

SLC38A3

SNAT4

SLC38A4

SNAT5

SLC38A5

SNAT7

SLC38A7

LAT3

SLC43A1

LAT4

SLC43A2

1 of 11

1 of 11

X
1 of 11

5 of 11

3 of 11

10 of 12

2 of 12

X
X

10 of 11

X
X

11 of 11
9 of 12

X

High

8 of 11

X

3 of 12

X

EMT6 and COMMA-1D Cell Lines

EMT6 is an epithelial cell line established from a murine mammary carcinoma that
developed in a BALB/cCRGL mouse after implantation of a hyperplastic mammary alveolar
nodule. The stock was obtained from ATCC (Manassus, VA). EMT6 has not been characterized
per breast cancer type. Observations and several experiments were undertaken to classify this
cell line as one of the four major molecular subtypes. While EMT6 has not been characterized, it
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has multiple characteristics of a basal, triple-negative breast cancer. These include: 1) basal
epithelial cells displaying an elongated and spiky appearance ("How Common is Breast
Cancer?,") (Figure 32); 2) expresses vimentin, a marker of epithelial–mesenchymal transition; 3)
has minimal expression of estrogen receptors (evidenced by lack of ATB0,+ amino acid
transporter (Karunakaran et al., 2011); 4) is glutamine dependent for proliferation as well as high
expression of glutamine synthetase (GLS) and glutamate ammonia ligase (GLUL) (van
Geldermalsen et al., 2016); and 5) lacks gene expression for the progesterone receptor.
This study cannot presume to fully determine the breast cancer type in the murine breast
cancer cell line, EMT6, as classification requires numerous studies that may provide conflicting
results. Several studies of human breast cancer report discordance between
immunohistochemical and transcriptional profiles. For example, of 142 triple-negative breast
cancers, 116 basal-like cancers were identified by one of three classifiers (histology,
immunohistochemistry or PAM50 gene signature), but only 13 cancers were classified as basallike by all three methods (Gazinska et al., 2013). Hence, depending on the classification method
used, the subtyping of breast cancers can vary. While there has been discordance between
estrogen receptor 1 expression and assessment of molecular subtype by RNA-based methods,
between 1 and 3% of estrogen 1-positive tumors display a basal-like phenotype (Perou et al.,
2000), (Sorlie et al., 2001), (Sorlie et al., 2003). Likewise, up to 60% of tumors classified as
HER2-positive by immunohistochemistry were classified otherwise by gene expression profiling
(de Ronde et al., 2010). However, using the techniques available for this study yielded results
that may form the basis for future investigation.
COMMA-1D, an epithelial cell line, was derived from mammary tissue of BALB/c
mice in the middle of pregnancy (Danielson, Oborn, Durban, Butel, & Medina, 1984). It exhibits
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characteristics of normal mammary epithelial cells, making it an excellent control for EMT6. It
also has normal duct morphogenesis in the cleared mammary fat pads of syngeneic mice.
A

B

Figure 32. Micrographs of the COMMA-1D and EMT6 cell lines. Both the non-cancerous
mammary cells from the BALB/c mouse (A) and the EMT6 mammary carcinoma (B) feature a
spiky morphology. As a breast carcinoma, this is one of the features that identifies EMT6 as a
basal type.

Comparison of Human and Mouse Genomes

Although mice have been used to make morphological and genetic comparisons with
humans, studies published in 2014 revealed differences based on expression profiles of 15 tissues
subjected to deep RNA sequencing. The transcriptome was examined for both protein-coding
and noncoding transcripts. Although commonalities were evident the results showed there is
considerable RNA expression diversity between humans and mice which reflect fundamental
physiological differences between the two organisms (Lin et al., 2014). High-throughput
sequencing assays showed that differences dominate similarities between the two species. Even

78

noncoding transcripts that are highly replicable are not conserved between mice and humans.
Regulatory information, in general, such as transcription factor binding, is highly diverged
(Borneman et al., 2007), (Cheng et al., 2014). Experimentation with a mouse model, therefore,
must extrapolate data and draw conclusions by referring to commonalities but expecting
physiological differences according each type of study.

The BALB/c Mouse Model

The BALB/c mouse is a laboratory-bred strain derived from Mus musculus in 1913
(Figure 33). The offspring have been inbred for over 200 generations and the breed is now one of
the top three most widely-used inbred strains for research. The substrain selected for this study is
called BALB/c which was transferred to Jackson Laboratory after 1940. Genetic markers
indicate that the three major substrains, including the BALB/c purchased for this study, have
diverged largely through mutation or residual heterozygosity ("Inbred Strains of Mice: BALB,"
2017). This mouse model is syngeneic with the EMT6 mammary epithelial cancer cell line
(Rockwell, Kallman, & Fajardo, 1972). It also maintains an intact immune system which
functions normally upon introduction of cancer cells, making this mouse an ideal model for
cancer research. Upon injection with EMT6 cells it can be expected that the physiological
responses will reflect the metabolic changes of the naturally occurring cancer transformation
process.
The female mouse has five pairs of nipples and mammary glands (Figures 34). Mammary
glands are embedded in adipose tissue (mammary fat pad) and consist of acini and ducts, which
give mammary glands tree-like structures. In virgin mice, the mammary gland consists of
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lactiferous ducts and a few acini, the lobules type 1. The acini and ducts of mammary glands are
lined by cuboidal epithelium, consisting of an inner layer of luminal secretory cells surrounded
by basal myoepithelial cells.

Figure 33. BALB/c mouse, a laboratory-bred strain derived from Mus musculus. BALB/c is
syngeneic with the mammary carcinoma cell line, EMT6. Therefore, physiological responses to
the cancer cell line, EMT6, will reflect the metabolic changes of the naturally occurring cancer
transformation process.
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Figure 34. Ventral side of the mouse displaying five sets of teats ("Mouse Mammary Gland
Anatomy,"). Mammary glands are embedded in adipose tissue (mammary fat pads).

Use of a Mouse Model

In vitro lab work with cell lines has provided basic information for metabolic activity for
many decades, and they have often been effective tools for drug discovery (Grigoriadis et al.,
2012). However, there are many limitations to applying cell line testing results to living
organisms. DNA methylation profiles of mammalian cell lines differ from the primary tissues of
origin, and the methylation profile continues to diverge with the passage of time in culture
(Nestor et al., 2015). For many cell lines, immortalization was effected via the simian virus 40
(SV40) large T antigen by associating with key cellular targets and altering the signaling
pathways they govern, and by inhibiting the p53 and Rb family of tumor suppressors (Ahuja,
Saenz-Robles, & Pipas, 2005). The effects are extended if transferred back into transgenic mice
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as SV40 oncoproteins may cause a range of dysfunction from hyperplasia to invasive carcinoma
accompanied by metastasis in a tissue dependent manner. Use of EMT6 in the syngeneic
COMMA-1D mouse model bypassed some of the negative effects associated with transferring
cell lines to a living organism.

Changes in Cultured Cell Lines

Reliance on cell lines to retain the molecular and functional features of the tissues they
were derived from has multiple limitations. It was recognized over thirty years ago, for example,
that de novo CGI methylation had occurred at 14 loci in two murine cell lines (Antequera, Boyes,
& Bird, 1990), and that mouse embryonic stem cell lines that are globally hypomethylated
become hypermethylated when grown in serum unless it is supplemented with small molecule
inhibitors (Habibi et al., 2013). A recent study showed that mouse embryonic fibroblasts in cell
culture exhibited rapid reprogramming of both epigenetic and transcriptional states with global 5
hydroxymethylcytosine (5hmC) erasure within three days of culture initiation. This was
proposed to be due to rapid loss of methylcytosine dioxygenase activity during adaptation of
mammalian cells to culture (Nestor et al., 2015). This is significant because the ability to
establish and maintain DNA methylation patterns is essential for normal development in
mammals (Li, Bestor, & Jaenisch, 1992). It had previously been recognized that mutations in the
ten-eleven translocation enzymes (TET1/2/3) responsible for the conversion of 5-methycytosine
(5mC) to 5hmC are frequent in many cancers and result in a hypermethylated promoter
phenotype (as seen in acute myeloid leukemia) (Pastor, Aravind, & Rao, 2013). The absence of a
demethylase activity also indicates that de novo methylation events would progressively
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accumulate at methylation-prone loci, which would likely affect gene expression upon RNA
studies (Rauch et al., 2007),. Based on the above considerations it was clear that in vivo studies
were essential to advance the understanding of glutamine transporter usage.

Transporters in COMMA-1D and EMT6

In addition to the eight amino acid transporters from three solute carrier families
investigated in the 13 HCC cell lines (see Part I, Family of Transporters, page 9), several
additional families and transporters were examined in the EMT6 cell line and the tumors formed
in the BALB/c mouse model upon injection of this cell line (Figure 41 and Table 5). To achieve
a base line of transporter abundance, the COMMA-1D cell line was used as the control for qRTPCR tests of nineteen glutamine transporters likely to test positive in the studies on mammary
carcinoma. To categorize EMT6 as a breast cancer type, three reproductive hormones and two
glutamine cycle enzymes were also tested (see Table 6).
(See Part I for a description of the SLC1, SLC3, SLC6, SLC7, and SLC38 families of
transporters, pages 10-13.) Besides LAT1, several other members of the SLC7 family were tested
including xCT (SLC7A11). Though this transporter does not transport glutamine, it uses
glutaminase (GLS) to deaminate intracellular glutamine for glutamate to drive the uptake of
cystine (two molecules of cysteine linked by a sulfhydryl bond) into the cell to support
glutathione biosynthesis. Another member of the SLC7, SLC7A4 or CAT4, is notable for its lack
of transport activity. Although this transporter has sequence homology to the other members of
the SLC7 family, it has not demonstrated any transport activity for cationic, neutral or anionic
amino acids (S. Wolf et al., 2002). While SLC7A4 does not need a second protein to be targeted
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to the plasma membrane, it may require an additional protein to activate its transport function.
Other members of the SLC7 family tested include y+LAT1, which mediates the sodiumindependent uptake of dibasic amino acids and sodium-dependent uptake of some neutral amino
acids; and y+LAT2, which mediates the sodium-independent uptake of dibasic amino acids and
sodium-dependent uptake of some neutral amino acids. Both y+LAT1 and y+LAT2 require coexpression with SLC3A2/4F2hc to mediate the uptake of arginine, leucine and glutamine.
An additional solute carrier family tested was SLC43. This family transports L-isomers of
neutral amino acids, including leucine, phenylalanine, valine and methionine in a sodium-,
chloride-, and pH-independent. Two members of this transporter family were tested: SLC43A1
(LAT3) and SLC43A2 (LAT4). The lactate transporter, monocarboxylate 1 (MCT-1), was also
tested as it may be upregulated during tumor proliferation.
Three additional members of the SLC6 family of transporters tested were B0AT1, an
electrogenic transporter which transports all neutral amino acids with a preference for large
neutral non-aromatic amino acids (Bohmer et al., 2005), sBAT, a sodium-dependent neutral
amino acid transporter, and B0AT3, which is generally only found in the brain though it does act
as a transporter of a broad range of neutral amino acids with affinity for proline, leucine, glycine,
alanine and glutamine (Parra et al., 2008), (Zaia & Reimer, 2009).
Gene expression studies using qRT-PCR were also completed to determine the presence
or absence of the progesterone receptor (Pgr), the estrogen 1 receptor (Esr1), and the epidermal
growth hormone receptor (Egfr) to determine the breast cancer subtype.

84

Figure 35. Solute Carrier (SLC) Transporters involved in glutamine transport. Transporter genes
(Italics), proteins, and the corresponding physiological transport activity (“Systems”) they
mediate (underline) as well as their substrates and transport mechanism are illustrated. BC-AA =
Branch chain amino acid; BC/A-AA = Branch chain/ Aromatic amino acid; SN-AA = Small
Neutral amino acid; Cat+-AA = Cationic amino acid; MeAIB = alpha-(methylamino)-isobutyric
acid. SLC7A11 (xCT), while not a glutamine transporter, uses glutaminase (GLS)-derived
glutamate to drive the uptake of cystine into the cell to support glutathione biosynthesis. The
crab icon indicates transporters implicated in cancer biology of the EMT6 breast carcinoma cell
line (Bode, 2017). (Adapted with permission.)
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Table 5
Seven amino acid transporter families investigated for gene expression in COMMA-1D, EMT6,
and in EMT6 unmodified and EMT6-GFP tumor tissue.
Transporter
Family
SLC1

Name

Characteristics

Excitatory Amino Acid Transporters

Sodium-dependent anionic and
neutral AAs

SLC3

Heavy chain
“Heavy chain” subunit chaperones of
heterodimeric amino acid transporters;
primarily SLC7 family members

SLC6

Sodium- and chloride-dependent
neurotransmitter transporter family

SLC7

Cationic and Heterodimeric Amino Acid Sodium-independent
Transporters (CATS and HATS)
cationic and large neutral AAs

SLC38

System N and A Transporters (SNATs)

Sodium-dependent
glutamine and other small
neutral AAs

SLC43

(System L-like Transporters)

Sodium-independent
large neutral AAs

Sodium-and chloride-dependent
cationic and neutral AAs
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Table 6.
Twenty-five transporters, enzymes, and receptors tested for mRNA via qRT-PCR studies.

Family
SLC1
SLC7
SLC7
SLC7
SLC7
SLC7
SLC7

Glutamine
Gene
SLC1A5
SLC7A4
SLC7A5
SLC7A6
SLC7A7
SLC7A8
SLC7A11

Protein
ASCT2
CAT4
LAT1
Y+2
Y+1
LAT2
xCT

SLC6
SLC6
SLC6
SLC6
SLC38
SLC38
SLC38
SLC38
SLC38
SLC38
SLC43
SLC43

SLC6A14
SLC6A15
SLC6A18
SLC6A19
SLC38A1
SLC38A2
SLC38A3
SLC38A4
SLC38A5
SLC38A7
SLC43A1
SLC43A2

ATB0,+
SBAT1
B0AT3
B0AT1
SNAT1
SNAT2
SNAT3
SNAT4
SNAT5
SNAT7
LAT3
LAT4

Lactate
Gene
Protein
SLC16A1 MCT1

Gln cycle
enzymes
GLS
GLUL

Receptors
Progesterone
Estrogen1
Epidermal growth factor

Effects of the Stroma on Tumor Development

Intercellular communication creates the environment for cell survival as well as
proliferation. Intercellular communication sets the pace for transformed cells to survive and to
thrive. Extracellular vesicles (EVs), such as exosomes, microvesicles and large oncosomes, are
involved in shuttling signals and molecules between transformed and stromal cells, which
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include fibroblasts, endothelial and immune cells (Wendler et al., 2017). Both cellular and
noncellular components make up the stroma (tumor microenvironment). Cellular components
include macrophages; fibroblasts; leukocytes; and endothelial cells. Noncellular components
include growth factors; proteolytic enzymes; extracellular matrix proteins; and inflammatory
cytokines (Yang, Nakamura, & Roberts, 2011). The interaction between tumor and
microenvironment is reciprocal and it is supported by genetic aberrations in the stroma (Moinfar
et al., 2000). However, the bulk of cancer stroma is composed of cancer-associated fibroblasts
(CAFs) which modulate biological activities in a tumor-stromal interaction affecting initiation,
angiogenesis, intravasation, and metastasis (Mao, Keller, Garfield, Shen, & Wang, 2013).
Studies show that the association of CAFs with cancer cells changes the biological properties of
both types of cells (Ishii et al., 2010). This results in a microenvironment that constantly adapts
as a tumor expands. EVs both promote drug resistance as well as transport molecules to healthy
tissue in the process of metastasis.

Lactate as an Alternative Metabolic Fuel

As the primary tumor expands, it outgrows the diffusion limits of its local blood supply,
leading to hypoxia which induces hypoxia inducible factor (HIF), a transcription factor that
initiates angiogenesis and other pro-survival mechanisms (Denko, 2008). At this point, cellular
metabolism shifts from dependence on the oxidative pathway to the glycolytic pathway,
Regulation is controlled via lactate dehydrogenase (LDH)-dependent conversion of lactate into
pyruvate and vice versa, and the transport of lactate into and out of cells through specific
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monocarboxylate transporters (MCTs). In tumors, the uptake of lactate into both tumor cells and
tumor endothelial cells occurs via the lactate transporter, MCT-1 (Draoui & Feron, 2011). As cMyc regulates glutamine in both cancerous cells and the associated stromal cells, such as cancerassociated fibroblasts (CAFs), the CAFs have lower intracellular glutathione levels which results
in an oxidizing environment that promotes stromally-produced growth factors that enhance
epithelial tumorigenesis (Valencia et al., 2014). Subsequent cascading events include high
glycolytic activity of CAFs that results in the accumulation of lactate which can be used
successfully as another fuel to drive energy production via oxidative phosphorylation. The
lactate is secreted into the extracellular space where it is then transported into adjacent cancer
cells via MCT-1 where it is converted to pyruvate and processed in the TCA cycle (Figure 36).
In addition, hypoxic cells distal to the blood vessel can convert glucose to lactate, which can then
be imported into cancer cells and converted to pyruvate for oxidation (Sonveaux et al., 2008)
The activation of c-Myc also promotes the transcription of target genes such as ASCT2, thus
MCT-1 inhibitors may be an appropriate form of therapy (Perez-Escuredo et al., 2016).
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Figure 36. Lactate conversion via monocarboxylate transporters 4 (MCT4) and 1 (MCT-1).
Glucose enters cancer-associated fibroblasts (CAFs) and glycolytic cancer cells from blood
vessels. It is converted to pyruvate followed by lactate via lactate dehydrogenase-5 (LDH-5).
Lactate is exported from the cell via MCT4 into the extracellular fluid, and then transported into
oxidative fibroblasts and cancer cells via MCT-1. Lactate is converted to pyruvate via lactate
dehydrogenase-1 (LDH-1); oxidative phosphorylation may then be completed via the
tricarboxylic acid (TCA) cycle in the mitochondria.

CHAPTER 6
MATERIALS AND METHODS

For Cell Culture; Cell Line Management; cDNA preparation; Extraction, Purification,
and Concentration of RNA; Electrophoresis; Quantitative Reverse Transcriptase-Real TimePolymerase Chain Reaction (qRT-PCR), please see Part I. Additional materials and methods
used in Part II follow.

Cell Lines

EMT6 is an epithelial cell line established from a murine mammary carcinoma that
developed in a BALB/cCRGL mouse after implantation of a hyperplastic mammary alveolar
nodule. COMMA-1D, compliments of Tissue Culture Shared Resource, Lombardi
Comprehensive Cancer Center, is also an epithelial murine cell line that was derived from the
mammary tissue of BALB/c mice which spontaneously immortalized and exhibits characteristics
of normal mammary epithelial cells.

Transfection with Green Fluorescent Protein (GFP) Expression Vector

MAX Efficiency® DH5α™ Competent Escherichia coli (E. coli) cells (ThermoFisher
Scientific, Chicago, IL) were transformed with the expression vector pCMV6-AC-mGFP,
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mammalian vector with C-terminal mGFP, (OriGene used to express GFP in long-term cell
cultures) (Figure 37). The plasmid constructs provided in an E. coli stock (60% glycerol) were
stored at -80° C. 5 µl of competent cells were combined 1 µl of the expression vector in 0.7 ml
tubes and incubated on ice for 30 minutes. The tubes were then heat-shocked at 42⁰ C for 30
seconds and then placed on ice. Each tube received 125 µl of SOC microbial growth medium and
the tubes were incubated on a rocker at 200 rpm for 1 hours at 37⁰ C. Individual bacterial
colonies were isolated by streaking cells on Luria broth (LB) (Fisher Scientific, Fair Lawn, NJ)
agar plates containing Ampicillin (100 μg/ml) and incubating the plates for 24 hours at 37o C.
Isolated colonies were picked for further expansion by inoculating 4 ml LB broth inoculated with
50 µg/ml Ampicillin which was then incubated for 24 hours on a rocker at 37o C. to be harvested
for purification of the plasmid stocks using the Wizard® Plus Midipreps DNA Purification
System (Promega, Madison, WI). The final elution volume was 600 μl in nuclease-free water
which was then concentrated to approximately 1 mg/ml via air centrifugation. Quantification of
the generated plasmid stocks was performed using a Nanodrop 2000 Micro-Volume UV-Vis
Spectrophotometer (Thermo Scientific, Waltham, MA), and the stocks were stored at -20° C.
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Figure 37. pCMV6-AC-mGFP, mammalian vector with C-terminal mGFP. The vector was
combined with competent Escherichia coli (E. coli) cells and heat-shocked to effect
transformation ("pCMV6-AC-mGFP, mammalian vector with C-terminal mGFP ", 2017).

Electroporation

The Neon® Transfection System by Invitrogen was used previously to optimize
electroporation in the SK Hep-1 HCC cell line by testing a range of DNA concentrations. As
EMT6 cells have a similar proliferation profile to SK Hep-1 cells, the same parameters were
selected for optimal results. The cells were trypsinized, counted and harvested by centrifugation.
Using a 100 μl tip, electroporations were done in serum-free Opti-MEM ®(Gibco, Grand Island,
NY) using cell-specific protocol and cells were plated in 6-well plates at a density of 1 x 105
cells per well. Forty-eight hours post-transfection, all wells were confluent and were fed

93

Geneticin-selective media (1.0 mg/ml). An EVOS™ FLoid™ Cell Imaging Station (Life
Technologies, ThermoFisher Scientific) with a green fluorescence channel set at 482/18 nm
excitation was used to visualize turboGFP expression in the cells. Only 10-20% of the
transfected cells survived. They were allowed to grow until confluent and continued to be
maintained in Geneticin-selective media (1.0 mg/ml). For long-term storage, antibiotic-free
medium supplemented with 10% dimethyl sulphoxide (DMSO) was added to the transfected
cells in Nunc® Cryotubes® (Sigma-Aldrich, St. Louis, MO), and the cell stocks were frozen at 80° C. After freezing, the cell stocks were stored in liquid nitrogen (-196° C).

Quantitative Reverse Transcriptase-Real Time-Polymerase Chain Reaction (qRT-PCR)
Specific Requirements

Two standards (controls) were used, as needed, for both the cell line and tissue tests: 1)
COMMA-1D for the EMT6 cell line; and EMT6 cell line for both EMT6 and EMT6-GFP tissue
samples.

Selection of Reference Genes for Murine Samples

geNorm reference gene selection protocol was followed as in Part I. Reverse-transcribed
mRNA samples from five murine cell lines, AML12, BNL, EMT6, INGA2, and SVA8 were
assessed for transporter expression using SYBR® green detection chemistry and then analyzed
using geNorm plus qbase+ software. The two most reliable reference genes, SDHA (Succinate
dehydrogenase complex, subunit A, flavoprotein variant) and ATP5B (ATP synthase subunit
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beta, mitochondrial) were used as mouse TaqMan probes: SDHA (Mm01352366_m1) and
ATP5B (Mm01160389_g1) (Life Technologies).

MTT Assays for Glutamine Dependence

MTT assays assessed viable cells present during the glutamine dependence study. Cells
were grown in forty-eight well plates and tetrazolium dye was reduced to insoluble formazan as
indication of metabolic activity. A 1:10 dilution working solution of the 5 mg/ml MTT stock
solution was prepared in phenol red-free DMEM medium, and 0.2 ml was added to each well of
the cells grown in a 48-well plate. The plates were Incubated at 37°C for 3 hours and then the
MTT working solution was removed. A solution of 0.04 M HCl in absolute isopropanol was
prepared and 0.2 ml of the acidic isopropanol was added to each well and the plate was placed on
a shaker for 5-10 minutes to dissolve the converted formazan. The plate was then read with an
Epoch spectrophotometer (Biotek Instruments, Inc., Winooski, VT) at 570 nm (with background
subtraction at 650 nm).

Growth Inhibition Studies with XTT Cell Proliferation Assay

Growth inhibition studies employed the XTT cell proliferation assay (Trevigen,
Gaithersburg, MD) which measures cell proliferation based upon the reduction of the tetrazolium
salt, 2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide, to a soluble
orange formazan dye. Three inhibitors were used to assess properties of EMT6 and COMMA 1D cell lines: 1) Glutamyl-p-nitroanilide Hydrochloride (GPNA), to reveal usage of ASCT2; 2)
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Na+-independent 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) to indicate System L
dependence; and 3) mifepristone (aka RU-486) to determine the presence or absence of
progesterone receptors. Using phenol-free high-glucose DMEM, four replicates in each of four
96-well cell culture plates were plated at a density of 8 x 103 cells/well to reach confluence after
72 hours. Plates were tested at 0, 24, 48, and 72 hours, and the media was changed daily. The
working solution was prepared using 5 ml/96 wells of 3X XTT reagent mixed with 50X XTT
activator. 50 µl of the working solution was applied directly to each well and the cell plate was
incubated for one hour at 37°C under 5% CO2 for one hour. Cell density was measured by
absorbance at 490 nm with a reference wavelength of 630 nm in an Epoch spectrophotometer
(Biotek Instruments, Inc., Winooski, VT).

In Vivo Studies with the BALB/c Mouse Model

All animal protocols in this study received IACUC (Illinois Institutional Animal Care and
Use Committee) approval, ORC #: LA16-0013. Lab animal handling training was provided by
Barrie P. Bode, Ph.D., who had 25 years of experience with rodent handling, anesthesia, surgery,
and tissue processing. The rationale for use of an animal model was to determine which
glutamine transporters are utilized by both the tumor and/or its adjacent stroma. Non-animal
alternatives (computer simulations, tissue culture) do not meet the needs of this protocol.
Animals are used to model a human condition, disease, disorder, or biological process which
cannot be investigated directly in humans for ethical reasons.
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Mouse Handling Protocol

Twenty 8-week old female BALB/cJ mice were purchased from Jackson Laboratory (Bar
Harbor, ME, to assure tumor growth in at least ten animals upon injection with EMT6 cells. Ten
of the (average 20 gram) female BALB/c mice were selected for initial studies to compare
mRNA results via qRT-PCR between two tumor populations: 1) EMT6-induced breast
carcinoma (using the unmodified cell line) and 2) EMT6 cells transfected with green fluorescent
protein (GFP). Unmodified versus GFP-positive EMT6 cells were used on contralateral sides to
assess whether forced GFP expression affects tumorigenesis. To this end, nine of the mice were
injected with 5 x 105 to 1 x 106 cells of the unmodified EMT6 cell line into the left inquinal
mammary fat pads and 5 x 105 to 1 x 106 cells of EMT6-GFP cells were injected into the right
inguinal mammary fat pads under anesthesia (100 mg/kg Ketamine/10 mg/kg xylazine). The
remaining ten mice received bilateral injections with 1 X 106 cells of EMT6-GFP cells into both
left and right ventral mammary fat pads. Three groups totaling nineteen mice were successfully
injected; one died soon after anesthetization. All mice were identified by ear tag during
anesthetization, as follows: Group 1 (three mice), #s 12, 13, and 14; Group 2 (six mice), #s 150156; and Group 3 (ten mice), #s 157-166. Upon recovery from anesthesia, the animals were
monitored for tumor growth daily by animal care staff and the researcher. They were also
checked daily to ensure that they appeared healthy, active, and alert and were observed for any
signs of physical or behavioral abnormalities. Any animal exhibiting signs of ill health or distress
was promptly humanely euthanized. Upon development of a palpable tumor, the animals were
monitored every three days, and tumor dimensions were recorded every 72 hours. Observation
continued until the breast tumors reached 0.5 – 1.0 cm3 (approximately 1 g or 5% of body
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weight) as assessed by caliper measurements. Breast tumors and adjacent tissue were removed
under anesthesia (100 mg/kg Ketamine/10 mg/kg xylazine) using surgical scissors, and the tissue
was snap-frozen in liquid nitrogen (for later processing in gene expression and protein analysis)
or immersed in 3.7% neutral-buffered formaldehyde solution for histological analysis. Upon
tumor removal euthanasia was performed using 80% CO2 inhalation from a gas cylinder and/or
thoracotomy. Death was ascertained by complete cessation of respiration.

RNA and Protein Extraction from Mouse Tumor Tissue

Snap frozen tumor tissues were homogenized in liquid nitrogen using a mortar and pestle.
The powdered tissue was then divided into two tubes, 3 parts for RNA extraction and 1 part for
protein extraction. RNA was extracted from tissues and cell lines in 1 ml of TRIzol® reagent
(Ambion, Life Technologies) followed by phase separation via the phenol-chloroform method.
After ethanol washes of the upper aqueous layer containing the RNA, the extract was
resuspended in DEPC water (diethylpyrocarbonate, used to inactivate RNase) to obtain a final
concentration of 4 μg/μl. Spectrophotometric readings of RNA (A260), as well as sample purity
readings (260 nm/280 nm) were obtained using the NanoDrop 2000 system (Thermo Fisher
Scientific; Chicago, IL). RNA was stored at -70o C.
For protein extraction, 500 µl of 1x lysis buffer and 1% protease inhibitor was added to
the protein tubes which were then vortexed at high speed for one minute and sonicated until the
sample was clear. The tubes were centrifuged at 13,000 x g in 4o C to remove solid cell
components. RNA and protein concentrations were measured using the Nanodrop
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spectrophotometer system. Final RNA concentrations were made using DEPC water to equal 4
µg/µl. The samples were stored at -80o C.

Cytology Analysis

Tissues fixed in formalin were processed and embedded in paraffin blocks. The paraffin
blocks of mammary tissues were thinly sectioned longitudinally and placed on slides for H&E
(hematoxylin and eosin) staining. The slides were analyzed and imaged using the EVOS™
FLoid™ Cell Imaging Station.

Tissue Processing for Fluorescence-Activated Cell Sorting

After excising the tumor and reserving portions for RNA, protein, and cytology studies,
the bulk of the tissue was submerged in normal DMEM and pressed through a sterile 60 nm
sieve. The pulverized tissue was added to a 15-ml tube with 10 ml of TryplE dissociation
enzyme with 1 mg/ml collagenase and 1% anti-micotic/antibiotic. The cell suspensions were
placed on a rotating mixer in a 37-degree incubator for 30 minutes. The digested tissue was
centrifuged and resuspended in PBS, and then transported on ice to the cell sorting facility at the
University of Illinois Chicago (UIC).

CHAPTER 7
RESULTS

Test for E-cadherin and Vimentin

The proteins associated with the epithelial-to-mesenchymal transition, vimentin, an
intermediate filament protein, and E-cadherin, a cell-to-cell adhesion glycoprotein, were tested in
COMMA-1D and EMT6 using a Western blot assay (Figure 38). Results showed that both
COMMA-1D and EMT6 expressed vimentin and only COMMA-1D expressed E-cadherin.
Whereas vimentin has been observed to coincide with metastasis in HCC (see Part I), it is also
part of the structure of the noncancerous cell line. Like HCC, however, E-cadherin was
extremely downregulated in EMT6. The expression of vimentin in EMT6 is another feature of a
triple negative breast cancer type.
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Figure 38. Western blot analysis of vimentin, an intermediate filament protein, and E-cadherin, a
cell-to-cell adhesion glycoprotein in COMMA-1D and EMT6. Results showed that vimentin was
expressed in both cell lines and that only COMMA-1D expressed E-cadherin.

Glutamine Dependence of the EMT6 Cell Line

Hensley et al (2013) has reported that luminal-type breast cancers are more likely to be
glutamine insensitive, while basal-type breast cancers are more frequently glutamine-dependent.
The enzyme, glutamate-ammonia ligase (GLUL), is utilized for synthesizing glutamine from
glutamate and ammonia when the cell is deprived of exogenous glutamine. Glutamine synthesis
in EMT6 was tested by growing cells in medium with increasing amounts of added glutamine,
from 0-2000 µm concentration (physiological concentration is ~1.0 mM). Western blot results
revealed a consistently diminished expression of GLUL as glutamine levels increased,
supporting the need for glutamine for growth and proliferation in EMT6 (Figure 39).
A 24-48 hour growth study using an XTT assay was also completed using eight
concentrations of glutamine (0 µM-200 µM) in DMEM media. Results showed abundance of
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EMT6 proliferation proportional to the concentration of glutamine (see Figure 40). The results of
these two studies supported the classification of the EMT6 cell line as basal versus luminal.

Figure 39. Western blot showing dependence of EMT6 on glutamine. Western blot results
showed decreased expression of the enzyme, glutamate ammonia ligase (GLUL), as glutamine
concentrations increased, supporting the dependence on glutamine of EMT6.
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Figure 40. Growth study using an XTT assay with 0-2000 µM glutamine. Results showed that
EMT6 was glutamine dependent as growth increased with successive concentrations of
glutamine.
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ASCT2 and LAT1 Assessed in COMMA-1D and EMT6

To provide a base line for the major glutamine and leucine transporters in the murine
mammary cell lines, a Western blot assay was performed for ASCT2 and LAT1 in COMMA-1D
and EMT6. Results showed distinct bands for ASCT2 in EMT6 and only faint bands in
COMMA-1D. LAT1 showed the opposite profile, with little protein expression in EMT6 and
prominent bands in COMMA-1D (Figure 41).

Figure 41. Western blot results for ASCT2 and LAT1 in EMT6 and COMMA-1D. ASCT2 is
more highly expressed in EMT6, while LAT1 is more abundant in COMMA-1D.
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Initial qRT-PCR Studies with EMT6 and COMMA-1D

Gene expression studies via qRT-PRC were first completed to determine abundance or
lack of expression of 25 transporters for glutamine, lactate, enzymes pertaining to the
intercellular glutamine cycle, and reproductive hormones, using the COMMA-1D cell line as a
control. Results for twenty-five transporters (Figure 42) showed that eight glutamine transporters
and the lactate transporter, MCT-1, were expressed in both cells lines with a greater abundance
in EMT6 (using COMMA-1D as the control). Expression of mRNA was revealed in six
transporters as well as CAT4 and xCT out of the 19 glutamine transporters tested. The relatively
abundant expression of CAT4 cannot be explained as it has no known transporter function. As
xCT, the cystine transporter, showed the highest mRNA abundance of all tested transporters it
may be inferred that the metabolic activity of this cell line results in excessive reactive oxygen
species that require the abundant production of the antioxidant, glutathione. Notably absent was
ATB0,+, the amino acid transporter specifically up-regulated in estrogen receptor (ER)-positive
breast cancer, as it is an ER target, for the transport of glutamine, leucine, and arginine
(Karunakaran et al., 2011). ER-positive breast cancer cells tend to up-regulate SLC6A14 to meet
their increased demand for these amino acids. EMT6 and its subsequent tumor component in
BALB/c mammary carcinoma tested negative for SLC6A14, indicating either minimal expression
of ER or an alternative transport route.
Of the two reproductive hormone receptors tested, progesterone receptor (Pgr) was absent
and abundance was low for estrogen 1 receptor (Esr1) (Figure 42A). Abundance was also low for
epidermal growth factor receptor (Egfr). Given the basal profile of this breast cancer cell line,
this supports the premise that 10% of basal tumors have some level of reproductive hormone
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receptor and epidermal growth factor receptor expression ("Breast Cancer Genetic Types,"
2016).
Two glutamine intercellular cycle enzymes were also tested: glutaminase (GLS), an
amidohydrolase enzyme which generates glutamate from glutamine, and the enzyme glutamateammonia ligase (GLUL) for synthesizing glutamine from glutamate and ammonia (Figure 42B).
Both enzymes tested positive, potentially indicating a triple negative breast cancer type.

Transporter mRNA in EMT6
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Figure 42. Transporter mRNA in EMT6. qPCR results of the comparison between EMT6 and
COMMA-1D (using COMMA-1D as the control). Results show expression levels for 8 of
nineteen glutamine transporters and the lactate transporter, MCT-1, that tested positive for
mRNA.
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Figure 43. The mRNA profile of reproductive hormone, epidermal growth factor receptors, and
enzymes of the intercellular glutamine cycle. A) Gene expression studies using qRT-PCR tested
the two reproductive hormone receptors and epidermal growth factor receptor usually lacking in
triple negative breast cancer. Results show an absence of the progesterone (Pgr) receptor, and
very low expression of the estrogen 1 receptor (Esr1) and the epidermal growth factor receptor
(Egfr). B) Two glutamine intercellular cycle enzymes were tested: glutaminase (GLS), an
amidohydrolase enzyme which generates glutamate from glutamine, and the enzyme glutamateammonia ligase (GLUL) for synthesizing glutamine from glutamate and ammonia. Both
enzymes tested positive, potentially indicating a triple negative breast cancer type.

Transport Studies with COMMA-1D and EMT6

Inhibitor studies

To determine the transporter(s) most active in the transport of glutamine into the
COMMA-1D (control) and EMT6 cell lines, a transport assay was completed with two inhibitors
at a concentration of 5 mM each. GPNA was used as an inhibitor of the SLC1 family,
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represented in this study by ASCT2, and BCH was used to inhibit cationic and neutral amino
acid transporters of the SLC7 family (SLC7A5-11), which includes System y(+)L, obligatory
exchangers of cationic amino acids (sodium-independent) and neutral amino acids (sodiumdependent), including glutamine (Figure 44). The results clearly indicated that ASCT2 was the
primary transporter of glutamine for both cell lines.

Glutamine (10 µM) transport in EMT6 and
COMMA-1D +/- BCH and GPNA
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Figure 44. BCH and GPNA inhibitor study. The inhibitors, BCH and GPNA, block transport of
glutamine via ASCT2 and transporters of the SLC7 family. Results show that the major
transporter of glutamine for both cells lines is ASCT2.

Amino acid inhibitors were also used to further define the glutamine transporter profile of
EMT6. Results showed that nearly all transport was inhibited by the competitive inhibitors of
ASCT2, alanine and glutamine, whereas histidine did not have a large effect on glutamine
transport in EMT6, indicating a lack of System N transporters (SNATS 3 and/or 5). COMMA-
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1D, in contrast, shows a 50% reduction in transport of glutamine in the presence of histidine,
indicating that System N transporters were lost during the process of malignant neoplasia (Figure
45).
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Figure 45. Amino acid competitive inhibition study in EMT6 and COMMA-1D. Alanine and
glutamine competitively inhibited ASCT2 transport in both EMT6 and COMMA-1D, and
histidine inhibited 50% of System N activity in COMMA-1D.

A pH study using a range of values from 6.0 to 8.0 revealed little inhibition of glutamine
transport in EMT6 versus a large effect on COMMA-1D (Figure 46). Results supported the
amino acid inhibitor study as the SLC38 family of transporters, which includes System A and
System N, are highly sensitive to pH changes whereas ASCT2 is not.
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Figure 46. An inhibitor study using pH levels with EMT6 and COMMA-1D. The study using a
range of values from 6.0 to 8.0 revealed minimal effects on glutamine transport in both EMT6
and COMMA-1D.

A substrate comparison study continued to confirm the previous results indicating that
EMT6 relies on ASCT2 versus System N transporters whereas COMMA-1D utilizes both sets of
transporters (Figure 47). ASCT2 will only tolerate sodium as a substrate whereas System N
tolerates lithium.
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Figure 47. Glutamine transport in EMT6 and COMMA-1D with three substrates. Results show
that EMT6 has a greater sensitivity to choline and lithium as substrates as ASCT2 will only
tolerate sodium whereas System N tolerates lithium as well.

Leucine Transport

Results of leucine transport in EMT6 revealed minimal transport of leucine with or
without inhibitors (Figure 48). While less than half is transported via System L (evidenced via
inhibition by leucine, phenylalanine, and BCH), a proportion is ostensibly transported via
ASCT2 as alanine and glutamine inhibit up to 75% of leucine transport. Inhibition by histidine
suggests a System A component, as well. While leucine is a common amino acid for activating
the growth-promoting kinase, mTOR1 (Nicklin et al., 2009), other System L (LAT1, LAT2,
y+LAT1, and y+LAT2) transporters as well as SLC43A1 (LAT3), SLC43A2 (LAT4), and B0AT1
may also be utilized to transport other mTORC1-activating amino acids such as phenylalanine,
arginine, and tryptophan.
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Figure 48. Leucine transport in EMT6. Results show minimal leucine transport in EMT6, and
nearly total inhibition of normal leucine transport with inhibitors.

Transport Kinetics Studies

Transporters follow Michaelis-Menton enzyme kinetics, therefore, a kinetics transport
study used concentration of glutamine versus transport velocity to compare the Km of COMMA1D with EMT6 (Figure 49). Results showed that EMT6 had a lower Km than COMMA-1D,
indicating three times higher affinity for glutamine. COMMA-1D had one-third the affinity and
three times the velocity before reaching saturation at 5 mM substrate concentration. As the
glutamine dependency study showed, EMT6 is dependent on glutamine for proliferation, and the
kinetics results reveal an efficient transport rate.
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Figure 49. Kinetics glutamine transport studies to compare the KM values of COMMA-1D and
EMT6. A) COMMA-1D had a 3x higher KM than EMT6, indicating only one-third the affinity
for glutamine. B) EMT6 kinetics results show 3x the affinity for glutamine as the non-cancerous
cell line, supporting the dependency of EMT6 on glutamine for proliferation.
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Fluorescence-Activated Cell Sorting (FACS)

To obtain two cell populations, tumor cells were transfected with GFP (Figure 50) for
laser identification in contrast with unlabeled stromal cells. After tumor excision, the bulk of the
tissue was digested in collagenase and TriplE Express dissociation enzyme and then transported
on ice to the cell sorting facility at the University of Illinois in Chicago (UIC). After the addition
of propidium iodide to identify the dead cells in the medium, an initial scan was taken to
determine the point of separation of the two cell types. Per the scatter plot (Figure 51, bottom
right) there was no clear delineation between the two cell types that would indicate that most
cells were of one type or the other. Therefore, the FACS cycler could not be programmed for
accurate cell sorting. As an alternative, the digested cells were plated and grown to confluence
for growth studies and the reserved snap frozen tissues were used for qRT-PCR analysis of
mixed cell types.

Figure 50. EMT6 cell line transfected with GFP protein.
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Figure 51. FACS initial cell count to determine the division between the two cell types, EMT6
and stroma. As seen on the lower right, there is no distinct division between cell type scatter
points, therefore, cells could not be sorted correctly.

Cytology of the BALB/c Breast Tumors

The breast tumor slides revealed a heterogeneous mix of cancer and stromal cells (Figure
52). Highly nucleated areas indicated carcinoma cells while sparsely nucleated areas indicated
stromal cells. An approximation of percentage of cancer versus stromal cells could not be made
due to the complex and uneven morphology shown on each slide. The results of gene expression

114

studies provided the information regarding the effects of the stroma on the original cancer cell
line.

Figure 52. Cytology of the BALB/c mammary carcinoma with associated stroma. Highly
nucleated areas indicated carcinoma cells while sparsely nucleated areas indicated stromal cells.
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Tumor Tissue Studies

qRT-PCR

After the growth, excision, and purification of tumor samples to yield RNA and protein,
the original 25 transporters were tested for mRNA expression using the combined RNA from
three samples that had remained intact during processing (Figure 53). Only RNA with 18S and
28S ribosomal bands were used for further testing.

Figure 53. Ethidium bromine-stained gel verifies intact RNA. Thirteen RNA samples were run
on an electrophoresis gel to determine the state of the extracted tumor RNA. Only five of the
samples revealed the 18S and 28S ribosomal bands, verifying integrity.

The unmodified EMT6 cell line was used as the control for both unmodified EMT6 tissue
RNA and EMT6-GFP tissue RNA. Results showed that both tissue samples had increased levels
of transporters compared to the cell line for all transporters originally tested with COMMA-1D
as the control. However, the GFP-transfected tumor RNA showed a greater abundance of mRNA
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expression in all GFP samples compared to unmodified EMT6 samples except for SNAT7 and
CAT4 (Figure 54).

Glutamine transporters and lactate transporter mRNA in mouse tissue
with unmodified EMT6 vs. EMT6-GFP

Expression level (Fold change)

7.000
6.000
5.000
4.000
3.000
2.000
1.000
0.000

Transporters

Figure 54. Glutamine transporter expression in unmodified vs. GFP-transfected EMT6 tumor
tissue. There is a greater abundance of mRNA expression in all GFP samples compared to
unmodified EMT6 except for SNAT7 and CAT4.

Esg1 receptor and Egfr reflected the same pattern. Expression levels were increased in
both tumor RNA types but were nearly twice as abundant in the GFP-transfected samples (Figure
55). The glutamine intercellular cycle enzymes revealed a different result in gene expression
(Figure 56). For GLUL, EMT6-GFP expressed more than twice the abundance of mRNA, while
GLS mRNA expression was less abundant in EMT6-GFP tissue.
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Reproductive hormone mRNA: EMT6 vs. EMT6-GFP

Expression level/fold change
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Figure 55. Estrogen 1 hormone receptor (Esg1) mRNA and epidermal growth factor receptor
(Egfr) mRNA in unmodified EMT6 and EMT6-GFP tumor tissue. Results showed higher levels
of both hormone receptors compared to the EMT6 cell line, with a greater abundance in EMT6GFP tumor tissue compared to the unmodified EMT6 tumor tissue.
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Figure 56. Comparison of GLUL and GLS in unmodified EMT6 tissue and EMT6-GFP. The
glutamine intercellular cycle enzyme RT-qPCR results show greater abundance for GLUL and
less abundance for GLS in EMT6-GFP tumor tissue samples compared to unmodified tumor.

Eight of the 11 transporters and receptors tested for mRNA that had not been expressed
in the COMMA-1D or EMT6 cell lines were expressed in both the unmodified EMT6 and
EMT6-GFP tumor RNA samples (see Table 7). As a norm, Comparative Ct Method, a.k.a. the
∆∆CT Method, is used to assess the expression levels obtained via RT-qPCR assays using four
samples: 1) Experimental sample + Target gene assay; 2) Experimental sample + Reference gene
assay; 3) Standard sample (control) + Target gene assay; and 4) Standard sample (control) +
Reference gene assay. This method uses the Ct, or threshold cycle, value from triplicate samples
as the basis for determining the expression level. Threshold cycle reflects the cycle number at
which the fluorescence generated within a reaction crosses the threshold (Figure 57). It is
inversely correlated to the logarithm of the initial copy number. The Ct value assigned to a
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particular well thus reflects the point during the reaction at which a sufficient number of
amplicons have accumulated to represent significant expression (Dorak, 2012). As there was no
control to determine expression levels for transporters not also expressed in the EMT6 cell line,
the raw Ct values were used to provide a comparison among a sample of seven transporters
calculated using the ∆∆CT Method and the seven newly-expressing transporters. As shown for
the GLS enzyme tested in Figure 57, Ct values comprise the x-axis of the cycler display, with the
value assigned to the threshold crossing indicative of target gene detection. A value lower on the
scale, therefore, indicates a greater abundance so that a Ct value of 23.28 indicates greater
mRNA abundance than a Ct value of 26.51. A dotted line at ~25 Ct indicates the range of values
showing moderate mRNA expression, however, any Ct value accompanied by a rising curve
spanning at least two Ct values at the linear phase is considered a valid indicator of target gene
presence. These results feature the effects of the microenvironment on transporters in this study
(Figure 58).
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Figure 57. Eppendorf II RT-qPCR cycler screen print show Ct values for the GLS enzyme. The
average Ct values for unmodified EMT6 tumor expression show a value of 23.28 (point of
crossing the threshold, boxed) compared to the average Ct value of 26.51 for the EMT6 cell line.
Results indicate greater abundance of tumor GLS compared to the EMT6 cell line.
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Table 7
Eight transporters and receptors show mRNA expression values in unmodified EMT6 and
EMT6-GFP tumor samples that had not been expressed in the COMMA-1D or EMT6 cell lines.
Gene

Protein

SLC7A8

LAT2

SLC38A1

SNAT1

SLC38A3

SNAT3

SLC38A4

SNAT4

SLC43A1

LAT3

SLC6A15

SBAT1

SLC6A19

B0AT1

Pgr

Progesterone
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Threshold cycle (Ct) value comparison among transporters in
BALB/c tumor samples
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Transporters
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Figure 58. Eight additional transporters expressed mRNA in tumor tissue compared with the
EMT6 cell line. Dashed line at ~25 Ct (threshold value) indicates significant mRNA expression
of the seven transporters (left side of chart) that tested positive in the EMT6 cell line to show
comparison with the Ct value range of the eight additional transporters expressed in the tumor
tissue samples only.

Inhibitor Growth Study Comparing Cell Lines to Tumor Tissue

Growth studies using the XTT assay tested three inhibitors from 0-72 hours using
COMMA-1D, EMT6, and EMT6-GFP tumor cells that were plated and grown to confluence.
Inhibitors included BCH (to determine System L contribution), GPNA (to inhibit ASCT2), and
mifepristone (to use as a partial agonist of the progesterone receptor in the absence of
progesterone). COMMA-1D showed a slower growth rate compared to EMT6 and EMT6-GFP
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tumor cells, with no System L contribution and significant ASCT2 activity (Figure 59 and 60).
Mifepristone failed to inhibit growth in both COMMA-1D and EMT6, indicating lack of a
progesterone receptor as had been previously shown in gene expression studies. EMT6 also
showed no System L activity but significant ASCT2 activity. Mifepristone also failed to inhibit
growth as expected via gene expression studies. EMT6-GFP tumor cells had equivalent results to
the EMT6 cell line, however, there was a slight reduction with mifepristone compared to the
control, possibly indicating activation of the progesterone receptor via the CAF component of the
stroma (Figure 61).

Inhibitor growth study with COMMA-1D
3.500
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3.000
2.500
2.000
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0.500
0.000
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GPNA
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Inhibitors/time
0 hr.

24 hr.

48 hr.

72 hr.

Figure 59. Inhibitor growth study of COMMA-1D with BCH, GPNA, and mifepristone, with
EtOH tested as a carrier of mifipristone. Results showed that BCH failed to inhibit growth,
indicating minimal transport via System L; GPNA inhibited ASCT2, indicating the presence of
ASCT2; and mifepristone failed to inhibit growth, indicating lack of a progesterone receptor.
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Inhibitor growth study with EMT6
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Figure 60. Inhibitor growth study of EMT6 with BCH, GPNA, and mifepristone, with EtOH
tested as a carrier of mifipristone. Results showed that BCH failed to inhibit growth, indicating
minimal transport via System L; GPNA inhibited ASCT2, indicating the presence of ASCT2;
and mifepristone failed to inhibit growth, indicating lack of a progesterone receptor.
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Inhibitor growth study in tumor tissue transfected with
GFP
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Figure 61. Inhibitor growth study of the GFP-transfected tumor cells with BCH, GPNA, and
mifepristone, with EtOH tested as a carrier. Results showed that BCH failed to inhibit growth,
indicating minimal transport via System L; GPNA inhibited ASCT2, indicating the presence of
ASCT2; and mifepristone partially inhibited growth at 72-hours, which may indicate activation
of the progesterone receptor through the CAF component of the stroma.

CHAPTER 8
DISCUSSION

The initial qRT-PCR studies with nineteen glutamine transporters, two reproductive
hormone receptors, one epidermal growth factor receptor, and two glutamine intercellular cycle
enzymes provided both a selection of expected results and several apparent anomalies. ASCT2
had the highest expression level among the glutamine transporters, and MCT-1, a transporter of
lactate as an alternative metabolic fuel, was one of the nine out of twenty transporters that
expressed mRNA levels. However, the transporter with the highest level of expression was
CAT4 of the SLC7 family of transporters which has not demonstrated any transport activity for
cationic, neutral or anionic amino acids (S. Wolf et al., 2002). Another member of the SLC7
family, xCT, had the second highest expression level. As a transporter of cystine it acts in
conjunction with glutaminase (GLS) to deaminate intracellular glutamine for glutamate to drive
the uptake of cystine into the cell to support glutathione biosynthesis. Looking at this data alone
appeared to support the hypothesis that neutralizing cellular acidity is a major if not primary
purpose of glutamine consumption in cancerous tissue (Huang et al., 2013). Initially comparing
EMT6 to COMMA-1D established the transporter profile, and comparing the tumor tissue
samples to EMT6 provided nearly the same profile of transporters but with different expression
levels, showing a universal increase from base line expression levels. In the latter comparison,
xCT was not as abundantly expressed compared to the other 8 transporters in mouse tissue,
however, there was an increase over the base line. As seen in HCC studies, translation and
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activity cannot be determined by the mRNA level alone, therefore, additional studies are needed
to determine if xCT plays a major or minor role in tumor metabolism.
The expression of seven transporters in the tumor samples that had not been expressed in
the cell lines indicates three possible conclusions. First, the transporters had originally been
expressed in the EMT6 cell line but had become lost or dysfunctional due to lack of need and
use. As the association of CAFs with cancer cells changes the biological properties of both types
of cells (Ishii et al., 2010), the disassociation upon cell line establishment may have altered both
structure and function. As discussed above, mouse embryonic fibroblasts in cell culture exhibited
rapid reprogramming of both epigenetic and transcriptional states with global 5
hydroxymethylcytosine (5hmC) erasure within three days of culture initiation (Nestor et al.,
2015), therefore, reverse reprogramming may have occurred with EMT6. Upon reintroduction
into the original host, the BALB/c mouse, EMT6 cells may have become reprogrammed.
The second conclusion is that the cells became programmed upon exposure to the stroma.
But it must also be remembered that in qRT-PCR, an expression level is in reference to another
cell line or tissue sample—a comparison and not an absolute value. In this case, COMMA-1D
was a mammary cell line with ostensibly normal properties that was compared with EMT6 that
displayed metastatic properties. Lower levels of a control transporter will result in higher
expression level reporting.
The third option is that the stromal cells of the heterogeneous tumor were expressing the
new transporters or have induced the cancer cells to express them, or both. It has been shown
that the association of CAFs with cancer cells changes the biological properties of both types of
cells (Ishii et al., 2010), and a recent study of CAFs determined that they can activate
progesterone receptors (Giulianelli et al., 2008). The transplantable ductal mammary tumor C4-
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HD was transplanted into BALB/c female mice with subsequent growth factors secreted by
CAFs that substituted for progestin-induced activation of the progesterone receptor. This resulted
in hormone independent mammary tumor growth, with similar results demonstrated in human
breast cancer cells. Not only does this result support the expected influence of stromal factors,
but having similarity in experimental outcome for both human and mouse studies provides an
inherent reason for testing in a mouse model; while there is considerable divergence in mRNA
expression between the two species which reflects fundamental physiological differences (Lin et
al., 2014), using a mouse model exposes unasked questions through the very process of inquiry.
In terms of all transporters and receptors studied, stable transfection with a plasmid
expressing GFP via electroporation had major consequences for mRNA expression levels. The
expression level change was not only seen at the tumor level; the greater proportion of EMT6GFP cell line results also indicated greater abundance of the transporters tested in comparison
with the unmodified cell line. One notable upregulation was the comparatively great abundance
of GLUL mRNA in the GFP-transfected tumor tissue accompanied by the low expression level
of GLS. One question to ask is why would a tumor developed from a stably transfected cancer
cell line need to synthesize more glutamine than a tumor from a non-transfected cell line? As the
GFP-plasmid included an antibiotic selection mechanism, one hypothesis is that acquired drug
resistance may promote or act in conjunction with the upregulation of nutrient transporters,
indicating a possible survival mechanism as cancer cells evolve to resist chemotherapeutic
treatment.
One of the successful outcomes of the group of studies completed with the EMT6 cell
line was the classification of triple-negative breast cancer (TNBC). While recognizing the
limitations of labeling the cell line based on a few studies, the experimental results are acceptable
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for the characteristics of 1) basal epithelial cells displaying an elongated and spiky appearance
("How Common is Breast Cancer?,"); 2) vimentin expression, indicative of a metastatic profile;
3) minimal expression of estrogen receptors (evidenced by lack of ATB0,+ amino acid transporter
expression (Karunakaran et al., 2011); 4) glutamine dependency for proliferation as well as high
expression of glutaminase (GLS) and glutamate ammonia ligase (GLUL) (van Geldermalsen et
al., 2016); and 5) lack of gene expression for the progesterone receptor. Growth studies with
mifepristone exemplified both the lack of effect of this progesterone inhibitor in the presence of
EMT6, and subsequent growth inhibition of the mouse EMT6-GFP tumor cells that had putative
CAF-activated progesterone receptors.
A more promising approach to definitive molecular classification is based on gene
expression profiles resulting from DNA methylation patterns (Szyf, 2012). Though RNA
transcription profiles have been used in breast cancer molecular diagnosis (Sudbo, Reith, &
Lingjaerde, 2001); (Prat & Perou, 2011); (Sorlie et al., 2001), DNA is more stable than RNA,
and DNA methylation profiles reflect long-term programming of the genome versus transcription
assays that represent activity at a specific time point. A distinction would still have to be made
between profiles determined from tissue samples versus tissue cells grown in culture; in vitro
studies have shown DNA methylation changes that are different in many instances from the
profile in vivo (Bork et al., 2010), (Grafodatskaya et al., 2010).
MCT-1 mRNA expression was slightly more abundant for both the unmodified EMT6
tumor and the EMT6-GFP tumor. Whereas glycolytic activity of CAFs is known to result in the
accumulation of lactate that can be transported to tumor cells via MCT-1 as fuel for oxidative
phosphorylation, the EMT6 tumor cells did not show high MCT-1 transcription levels. Again, as
noted in studies with HCC, there may be no universal comparison between mRNA abundance
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and protein levels, often with a substantial margin of difference, and discordance may be evident
at the activity level as well. More detailed studies in the future will be necessary to determine the
extent of lactate uptake.
Of twenty-five transporters, receptors, and enzymes investigated for mRNA, only three
did not test positive in either the cell lines or the tumor tissue samples: SNAT5, ATB0,+ , and
BOAT3. It is significant, therefore, that 88% of the experimental target genes were active in
supporting tumor survival. This indicates that testing should be both deep and broad so that a
barrier administered in one area does not leave exposure in another.
The applicability of these studies to the human population is unknown and only further
studies replicated with human breast carcinoma will provide the answers. A significant lesson
from the experiment is the effect of transfection, with a putative drug resistance response on
transporter expression, that recommends caution in future experimentation with stably
transfected cells.

CHAPTER 9

GENERAL CONCLUSION

Transport physiology is affected by numerous factors: intra- and intercellular abundance
of substrate; whether the transporter is also a transceptor (as in SNAT2); mutation (in the case of
beta-catenin and Hep G2); pH conditions; signaling cascades (e.g., binding of cysteine to a
secondary site on ASCT2); and electrogenic forces/membrane potential. Suppression of one
transporter, such as ASCT2, may cause the upregulation of another in response, or stromal
factors may activate a new set of transporters resulting in the profound resilience of cancer cells.
In HCC, eight tested transporters were responsible for maintaining glutamine and other neutral
amino acid homeostasis during the complexities of cancerous transformation. Sixteen of the
nineteen amino acid transporters that were tested for breast cancer in this study were positive for
mRNA transcription, therefore, it is probable that other untested amino acid transporters were
operating in HCC as well. The more pathways that can be identified for amino acid uptake the
better the knowledge base for treatment options.
Determining the characteristics of the HCC cells lines and the breast cancer cell line was
pertinent to understanding the physiology. As seen in the in vivo results for the breast cancer
study, it was essential to determine not only the multitude of nutrient supply channels but the
intricate mechanisms of cancer’s support system.
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No single approach, or even several, renders an absolute or final word on the multifaceted
disease of cancer due to the plasticity and resilience of the evolving malignant cell and its
recruited stroma. As the cancer consistently adapts to its deranged conditions so must the
researcher respond with ever more obstructive therapies.
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